SynGap Missense Server

Table of SynGAP1 Isoform α2 (UniProt Q96PV0-1) Missense Variants.

c.dna Variant SGM Consensus Domain ClinVar gnomAD ESM1b AlphaMissense REVEL FoldX Rosetta Foldetta PremPS PROVEAN PolyPhen-2 HumDiv PolyPhen-2 HumVar FATHMM SIFT PAM Physical SASA Normalized B-factor backbone Normalized B-factor sidechain SynGAP Structural Annotation DOI
Clinical Status Review Subm. ID Allele count Allele freq. LLR score Prediction Pathogenicity Class Optimized Score Prediction Average ΔΔG Prediction StdDev ΔΔG Prediction ΔΔG Prediction ΔΔG Prediction Score Prediction pph2_prob Prediction pph2_prob Prediction Nervous System Score Prediction Prediction Status Conservation Sequences PAM250 PAM120 Hydropathy Δ MW Δ Average Δ Δ StdDev Δ StdDev Secondary Tertiary bonds Inside out GAP-Ras interface At membrane No effect MD Alert Verdict Description
c.3397A>GI1133VLikely BenignBenign 16-33443949-A-G221.48e-5-3.362Likely Benign0.067Likely BenignLikely Benign0.180Likely Benign0.06Neutral0.007Benign0.007Benign5.47Benign0.58Tolerated4.32343-0.3-14.0310.1016/j.ajhg.2020.11.011
c.3404A>CK1135TLikely BenignConflicting 26-33443956-A-C16.75e-7-4.778Likely Benign0.779Likely PathogenicLikely Benign0.210Likely Benign-0.90Neutral0.411Benign0.321Benign5.46Benign0.10Tolerated4.3220-13.2-27.07
c.3405G>CK1135NLikely BenignUncertain 1-5.715Likely Benign0.960Likely PathogenicLikely Pathogenic0.166Likely Benign-0.97Neutral0.411Benign0.321Benign5.43Benign0.07Tolerated4.322100.4-14.07
c.3410A>CH1137PLikely BenignBenign 16-33444445-A-C127.44e-6-2.098Likely Benign0.054Likely BenignLikely Benign0.419Likely Benign-1.93Neutral0.925Possibly Damaging0.703Possibly Damaging5.29Benign0.00Affected4.324-201.6-40.02
c.3424T>CS1142PLikely BenignLikely Benign 16-33444459-T-C16.20e-7-2.713Likely Benign0.222Likely BenignLikely Benign0.107Likely Benign-2.19Neutral0.918Possibly Damaging0.761Possibly Damaging2.64Benign0.00Affected4.324-11-0.810.04
c.3434A>GN1145SLikely BenignUncertain 16-33444469-A-G21.24e-6-0.989Likely Benign0.126Likely BenignLikely Benign0.308Likely Benign-1.15Neutral0.997Probably Damaging0.989Probably Damaging5.55Benign0.89Tolerated4.324112.7-27.03
c.3442A>TM1148LLikely BenignUncertain 1-1.777Likely Benign0.093Likely BenignLikely Benign0.068Likely Benign-1.13Neutral0.016Benign0.016Benign2.62Benign0.00Affected4.322421.9-18.03
c.3449C>TA1150VLikely BenignUncertain 16-33444484-C-T31.86e-6-3.648Likely Benign0.192Likely BenignLikely Benign0.066Likely Benign-2.22Neutral0.114Benign0.055Benign2.32Pathogenic0.04Affected3.775002.428.05
c.3484C>TP1162SLikely BenignUncertain 1-2.118Likely Benign0.913Likely PathogenicAmbiguous0.215Likely Benign-1.93Neutral1.000Probably Damaging0.999Probably Damaging2.73Benign0.55Tolerated3.8831-10.8-10.04
c.3494C>TS1165LLikely BenignConflicting 2-2.984Likely Benign0.793Likely PathogenicAmbiguous0.166Likely Benign-2.01Neutral0.998Probably Damaging0.992Probably Damaging2.60Benign0.33Tolerated3.883-3-24.626.0810.1016/j.ajhg.2020.11.011
c.3502A>GI1168VLikely BenignUncertain 1-3.263Likely Benign0.524AmbiguousLikely Benign0.363Likely Benign-0.14Neutral0.876Possibly Damaging0.643Possibly Damaging5.47Benign0.84Tolerated3.88343-0.3-14.03
c.3508A>GS1170GLikely BenignCoiled-coilUncertain 1-4.288Likely Benign0.221Likely BenignLikely Benign0.349Likely Benign-0.81Neutral0.241Benign0.229Benign5.31Benign0.54Tolerated4.324100.4-30.03
c.3511G>AA1171TLikely BenignCoiled-coilUncertain 1-3.658Likely Benign0.149Likely BenignLikely Benign0.201Likely Benign-0.48Neutral0.245Benign0.138Benign5.45Benign0.07Tolerated4.32410-2.530.03
c.3511_3512delinsTGA1171CLikely BenignCoiled-coilUncertain 1-5.363Likely Benign0.496AmbiguousLikely Benign-1.16Neutral0.978Probably Damaging0.825Possibly Damaging5.32Benign0.02Affected4.324-200.732.06
c.3520G>AE1174KLikely BenignCoiled-coilUncertain 16-33444555-G-A21.24e-6-4.345Likely Benign0.898Likely PathogenicAmbiguous0.442Likely Benign-1.59Neutral0.962Probably Damaging0.367Benign5.52Benign0.03Affected4.32201-0.4-0.94
c.3529G>AE1177KLikely BenignCoiled-coilUncertain 1-3.413Likely Benign0.944Likely PathogenicAmbiguous0.560Likely Pathogenic-1.75Neutral0.905Possibly Damaging0.637Possibly Damaging5.44Benign0.11Tolerated4.32201-0.4-0.94
c.3567G>CE1189DLikely BenignCoiled-coilLikely Benign 16-33444602-G-C31.86e-6-3.582Likely Benign0.461AmbiguousLikely Benign0.359Likely Benign-1.42Neutral0.992Probably Damaging0.989Probably Damaging5.30Benign0.25Tolerated3.824320.0-14.03
c.3572G>AR1191QLikely BenignCoiled-coilUncertain 26-33444607-G-A95.58e-6-1.069Likely Benign0.943Likely PathogenicAmbiguous0.343Likely Benign-1.41Neutral0.998Probably Damaging0.992Probably Damaging2.68Benign0.08Tolerated3.824111.0-28.06
c.3574C>GL1192VLikely BenignCoiled-coilUncertain 1-4.132Likely Benign0.471AmbiguousLikely Benign0.041Likely Benign-0.89Neutral0.779Possibly Damaging0.527Possibly Damaging2.69Benign0.16Tolerated210.4-14.03
c.3607C>GH1203DLikely BenignCoiled-coilUncertain 1-6.729Likely Benign0.525AmbiguousLikely Benign0.403Likely Benign-1.89Neutral0.473Possibly Damaging0.265Benign5.51Benign0.24Tolerated3.7751-1-0.3-22.05
c.3607C>TH1203YLikely BenignCoiled-coilUncertain 16-33446599-C-T21.24e-6-6.834Likely Benign0.149Likely BenignLikely Benign0.233Likely Benign-1.52Neutral0.006Benign0.011Benign5.55Benign0.10Tolerated3.775201.926.03
c.3631A>GM1211VLikely BenignCoiled-coilBenign 16-33446623-A-G31.86e-6-2.101Likely Benign0.258Likely BenignLikely Benign0.412Likely Benign-0.29Neutral0.932Possibly Damaging0.949Probably Damaging5.43Benign0.72Tolerated3.775122.3-32.06
c.3633G>AM1211ILikely BenignCoiled-coilUncertain 16-33446625-G-A31.86e-6-1.537Likely Benign0.764Likely PathogenicLikely Benign0.298Likely Benign-0.42Neutral0.969Probably Damaging0.968Probably Damaging5.40Benign1.00Tolerated3.775122.6-18.03
c.3638A>CN1213TLikely BenignCoiled-coilConflicting 26-33446630-A-C462.85e-5-5.428Likely Benign0.266Likely BenignLikely Benign0.097Likely Benign-1.08Neutral0.959Probably Damaging0.721Possibly Damaging2.74Benign1.00Tolerated3.775002.8-13.00
c.3638A>GN1213SLikely BenignCoiled-coilBenign 16-33446630-A-G138.05e-6-4.086Likely Benign0.081Likely BenignLikely Benign0.094Likely Benign-0.56Neutral0.906Possibly Damaging0.551Possibly Damaging2.82Benign0.68Tolerated3.775112.7-27.0310.1016/j.ajhg.2020.11.011
c.3662G>AR1221QLikely BenignCoiled-coilConflicting 26-33446654-G-A42.48e-6-5.491Likely Benign0.115Likely BenignLikely Benign0.078Likely Benign-1.46Neutral0.836Possibly Damaging0.153Benign2.56Benign0.12Tolerated3.775111.0-28.06
c.36C>GS12RLikely BenignUncertain 16-33420300-C-G42.59e-6-4.033Likely Benign0.500AmbiguousLikely Benign0.097Likely Benign-0.30Neutral0.000Benign0.000Benign4.09Benign0.00Affected4.3210-1-3.769.11
c.3705G>AM1235ILikely BenignCoiled-coilUncertain 1-4.312Likely Benign0.310Likely BenignLikely Benign0.027Likely Benign-1.44Neutral0.139Benign0.056Benign2.69Benign0.04Affected3.775122.6-18.03
c.371C>TA124VLikely BenignConflicting 26-33432236-C-T95.58e-6-4.259Likely Benign0.138Likely BenignLikely Benign0.073Likely Benign-1.52Neutral0.173Benign0.009Benign4.07Benign0.03Affected3.615002.428.05
c.373C>TP125SLikely BenignUncertain 1-3.769Likely Benign0.238Likely BenignLikely Benign0.121Likely Benign-3.57Deleterious0.580Possibly Damaging0.140Benign2.86Benign0.02Affected3.6151-10.8-10.04
c.37A>GI13VLikely BenignUncertain 1-2.497Likely Benign0.105Likely BenignLikely Benign0.110Likely Benign0.01Neutral0.000Benign0.000Benign4.25Benign0.00Affected43-0.3-14.03
c.380G>AR127QLikely BenignUncertain 16-33432245-G-A63.72e-6-1.711Likely Benign0.320Likely BenignLikely Benign0.037Likely Benign-1.04Neutral0.006Benign0.001Benign4.04Benign0.02Affected3.744111.0-28.06
c.3824G>AR1275QLikely BenignUncertain 16-33447872-G-A21.29e-6-4.928Likely Benign0.121Likely BenignLikely Benign0.103Likely Benign-1.72Neutral0.898Possibly Damaging0.147Benign2.59Benign0.03Affected3.775111.0-28.06
c.382C>AP128TLikely BenignUncertain 16-33432247-C-A16.20e-7-4.217Likely Benign0.267Likely BenignLikely Benign0.075Likely Benign-0.96Neutral0.952Possibly Damaging0.500Possibly Damaging4.19Benign0.35Tolerated3.744-100.93.99
c.3835G>AA1279TLikely BenignUncertain 26-33447883-G-A21.29e-6-4.871Likely Benign0.071Likely BenignLikely Benign0.178Likely Benign-0.30Neutral0.001Benign0.000Benign2.71Benign0.09Tolerated3.77510-2.530.03
c.3846G>CE1282DLikely BenignUncertain 16-33447894-G-C16.44e-7-3.879Likely Benign0.074Likely BenignLikely Benign0.104Likely Benign-1.26Neutral0.112Benign0.036Benign2.70Benign0.39Tolerated3.775320.0-14.03
c.3848C>TP1283LLikely BenignBenign 16-33447896-C-T322.06e-5-3.740Likely Benign0.093Likely BenignLikely Benign0.047Likely Benign-1.04Neutral0.005Benign0.003Benign2.76Benign0.06Tolerated3.775-3-35.416.04
c.3858A>TE1286DLikely BenignConflicting 46-33447906-A-T1439.22e-5-4.010Likely Benign0.081Likely BenignLikely Benign0.036Likely Benign1.02Neutral0.001Benign0.004Benign2.96Benign1.00Tolerated3.775320.0-14.0310.1016/j.ajhg.2020.11.011
c.3859C>AP1287TLikely BenignUncertain 16-33447907-C-A-3.940Likely Benign0.077Likely BenignLikely Benign0.044Likely Benign-0.22Neutral0.126Benign0.041Benign2.78Benign0.04Affected3.775-100.93.99
c.3860C>TP1287LLikely BenignConflicting 26-33447908-C-T-2.800Likely Benign0.117Likely BenignLikely Benign0.061Likely Benign-1.66Neutral0.021Benign0.017Benign2.76Benign0.02Affected3.775-3-35.416.04
c.3902C>AP1301HLikely BenignConflicting 26-33451776-C-A53.10e-6-5.756Likely Benign0.104Likely BenignLikely Benign0.232Likely Benign-1.13Neutral0.642Possibly Damaging0.378Benign2.79Benign0.04Affected3.7750-2-1.640.02
c.3902C>GP1301RLikely BenignUncertain 16-33451776-C-G159.30e-6-4.753Likely Benign0.162Likely BenignLikely Benign0.076Likely Benign-1.13Neutral0.077Benign0.059Benign2.81Benign0.10Tolerated3.7750-2-2.959.07
c.3907G>AG1303SLikely BenignUncertain 1-2.271Likely Benign0.125Likely BenignLikely Benign0.155Likely Benign-0.19Neutral0.649Possibly Damaging0.433Benign2.84Benign0.18Tolerated10-0.430.03
c.3913A>GT1305ALikely BenignConflicting 46-33451787-A-G301.86e-5-2.692Likely Benign0.055Likely BenignLikely Benign0.069Likely Benign1.74Neutral0.000Benign0.001Benign3.24Benign1.00Tolerated3.775102.5-30.03
c.3920C>AP1307QLikely BenignUncertain 16-33451794-C-A-4.227Likely Benign0.114Likely BenignLikely Benign0.192Likely Benign-0.88Neutral0.988Probably Damaging0.765Possibly Damaging2.82Benign0.03Affected3.7750-1-1.931.01
c.3920C>TP1307LLikely BenignBenign 16-33451794-C-T116.82e-6-4.044Likely Benign0.144Likely BenignLikely Benign0.292Likely Benign-1.49Neutral0.779Possibly Damaging0.220Benign2.82Benign0.04Affected3.775-3-35.416.04
c.3929C>TT1310MLikely BenignBenign 16-33451803-C-T171.05e-5-4.822Likely Benign0.117Likely BenignLikely Benign0.069Likely Benign2.19Neutral0.021Benign0.005Benign2.98Benign0.93Tolerated3.775-1-12.630.09
c.3932T>CL1311PLikely BenignLikely Benign 16-33451806-T-C16.21e-7-1.831Likely Benign0.079Likely BenignLikely Benign0.123Likely Benign-0.52Neutral0.579Possibly Damaging0.335Benign2.72Benign0.18Tolerated3.775-3-3-5.4-16.04
c.3941C>TP1314LLikely BenignLikely Benign 16-33451815-C-T21.24e-6-4.040Likely Benign0.118Likely BenignLikely Benign0.049Likely Benign-0.20Neutral0.421Benign0.066Benign4.19Benign0.05Affected3.775-3-35.416.04
c.3943T>CW1315RLikely BenignUncertain 10.205Likely Benign0.660Likely PathogenicLikely Benign0.114Likely Benign1.31Neutral0.000Benign0.001Benign4.37Benign0.91Tolerated3.7752-3-3.6-30.03
c.3949G>AG1317SLikely BenignConflicting 36-33451823-G-A16.26e-7-3.522Likely Benign0.145Likely BenignLikely Benign0.092Likely Benign-2.45Neutral0.127Benign0.045Benign4.08Benign0.00Affected3.77510-0.430.03
c.3956C>GA1319GLikely BenignUncertain 26-33451830-C-G-3.927Likely Benign0.084Likely BenignLikely Benign0.128Likely Benign-0.74Neutral0.819Possibly Damaging0.581Possibly Damaging4.07Benign0.06Tolerated3.77510-2.2-14.03
c.3958C>TP1320SLikely BenignUncertain 16-33451832-C-T21.28e-6-4.928Likely Benign0.073Likely BenignLikely Benign0.097Likely Benign-0.69Neutral0.980Probably Damaging0.968Probably Damaging4.25Benign0.00Affected3.7751-10.8-10.04
c.3961C>TP1321SLikely BenignUncertain 26-33451835-C-T106.46e-6-4.897Likely Benign0.077Likely BenignLikely Benign0.049Likely Benign0.68Neutral0.028Benign0.004Benign4.27Benign0.71Tolerated3.7751-10.8-10.0410.1016/j.ajhg.2020.11.011
c.3962C>AP1321QLikely BenignBenign 16-33451836-C-A16.58e-7-5.594Likely Benign0.079Likely BenignLikely Benign0.055Likely Benign-0.74Neutral0.659Possibly Damaging0.034Benign4.24Benign0.09Tolerated3.7750-1-1.931.01
c.3964G>CA1322PLikely BenignBenign 16-33451838-G-C-1.153Likely Benign0.063Likely BenignLikely Benign0.090Likely Benign0.03Neutral0.000Benign0.000Benign4.15Benign0.23Tolerated3.7751-1-3.426.04
c.3970C>TP1324SLikely BenignLikely Benign 16-33451844-C-T53.26e-6-5.451Likely Benign0.068Likely BenignLikely Benign0.049Likely Benign0.35Neutral0.225Benign0.092Benign4.33Benign0.00Affected4.3211-10.8-10.04
c.3974C>TP1325LLikely BenignUncertain 16-33451848-C-T-5.256Likely Benign0.085Likely BenignLikely Benign0.146Likely Benign-1.05Neutral0.000Benign0.000Benign4.05Benign0.00Affected4.321-3-35.416.04
c.3977C>AP1326QLikely BenignUncertain 16-33451851-C-A16.40e-7-5.422Likely Benign0.128Likely BenignLikely Benign0.138Likely Benign-0.86Neutral0.999Probably Damaging0.994Probably Damaging3.62Benign0.00Affected3.775-10-1.931.01
c.3977C>GP1326RLikely BenignUncertain 1-5.097Likely Benign0.240Likely BenignLikely Benign0.133Likely Benign-0.82Neutral0.999Probably Damaging0.994Probably Damaging3.62Benign0.00Affected3.7750-2-2.959.07
c.3977C>TP1326LLikely BenignUncertain 1-5.541Likely Benign0.115Likely BenignLikely Benign0.117Likely Benign-1.06Neutral0.999Probably Damaging0.994Probably Damaging3.62Benign0.00Affected3.775-3-35.416.04
c.3979C>TP1327SLikely BenignUncertain 16-33451853-C-T-4.744Likely Benign0.131Likely BenignLikely Benign0.092Likely Benign0.28Neutral0.980Probably Damaging0.857Possibly Damaging4.25Benign0.71Tolerated3.7751-10.8-10.04
c.3980C>TP1327LLikely BenignUncertain 16-33451854-C-T21.28e-6-5.264Likely Benign0.242Likely BenignLikely Benign0.142Likely Benign-1.24Neutral0.994Probably Damaging0.908Possibly Damaging4.12Benign0.10Tolerated3.775-3-35.416.04
c.3983G>AR1328QLikely BenignUncertain 36-33451857-G-A351.49e-4-2.921Likely Benign0.273Likely BenignLikely Benign0.043Likely Benign-1.02Neutral0.799Possibly Damaging0.098Benign4.12Benign0.03Affected3.775111.0-28.06
c.3983G>CR1328PLikely BenignBenign 16-33451857-G-C-1.220Likely Benign0.466AmbiguousLikely Benign0.060Likely Benign-2.01Neutral0.927Possibly Damaging0.452Possibly Damaging4.06Benign0.01Affected3.7750-22.9-59.07
c.3G>AM1ILikely BenignConflicting 3-5.397Likely Benign0.227Likely Benign-0.17Neutral0.001Benign0.000Benign4.25Benign0.00Affected4.321212.6-18.03
c.4006G>AE1336KLikely BenignBenign 26-33451880-G-A64.20e-6-4.697Likely Benign0.977Likely PathogenicLikely Pathogenic0.272Likely Benign-2.44Neutral0.748Possibly Damaging0.079Benign3.23Benign0.00Affected3.77501-0.4-0.94
c.4008G>CE1336DLikely BenignLikely Benign 1-3.344Likely Benign0.596Likely PathogenicLikely Benign0.062Likely Benign-1.92Neutral0.001Benign0.003Benign3.30Benign0.00Affected3.775230.0-14.03
c.4013G>AR1338QLikely BenignConflicting 36-33451887-G-A128.40e-6-3.494Likely Benign0.317Likely BenignLikely Benign0.076Likely Benign-1.87Neutral0.896Possibly Damaging0.194Benign3.81Benign0.02Affected3.775111.0-28.06
c.401G>AS134NLikely BenignUncertain 1-5.534Likely Benign0.813Likely PathogenicAmbiguous0.075Likely Benign-1.62Neutral0.001Benign0.002Benign3.90Benign0.00Affected3.61511-2.727.03
c.4021G>AA1341TLikely BenignConflicting 36-33451895-G-A453.44e-5-3.224Likely Benign0.081Likely BenignLikely Benign0.099Likely Benign-0.58Neutral0.000Benign0.000Benign4.09Benign0.03Affected3.77510-2.530.03
c.4021G>TA1341SLikely BenignUncertain 16-33451895-G-T-2.867Likely Benign0.078Likely BenignLikely Benign0.099Likely Benign0.80Neutral0.000Benign0.001Benign4.40Benign1.00Tolerated3.77511-2.616.00
c.416G>AS139NLikely BenignUncertain 16-33432713-G-A32.22e-6-4.584Likely Benign0.688Likely PathogenicLikely Benign0.109Likely Benign-0.75Neutral0.149Benign0.047Benign4.14Benign0.24Tolerated3.61511-2.727.03
c.43G>AA15TLikely BenignUncertain 16-33420307-G-A42.60e-6-3.720Likely Benign0.125Likely BenignLikely Benign0.086Likely Benign-0.08Neutral0.602Possibly Damaging0.017Benign4.16Benign0.00Affected4.32110-2.530.03
c.43G>CA15PLikely BenignUncertain 1-3.436Likely Benign0.097Likely BenignLikely Benign0.146Likely Benign-0.23Neutral0.880Possibly Damaging0.123Benign4.09Benign0.00Affected1-1-3.426.04
c.44C>TA15VLikely BenignUncertain 16-33420308-C-T16.49e-7-3.560Likely Benign0.161Likely BenignLikely Benign0.105Likely Benign0.20Neutral0.602Possibly Damaging0.015Benign4.19Benign0.00Affected4.321002.428.05
c.453C>AD151ELikely BenignUncertain 1-5.662Likely Benign0.886Likely PathogenicAmbiguous0.142Likely Benign-2.02Neutral0.984Probably Damaging0.967Probably Damaging3.99Benign0.11Tolerated3.615320.014.03
c.458C>AT153NLikely BenignConflicting 3-0.739Likely Benign0.226Likely BenignLikely Benign0.161Likely Benign0.88Neutral0.888Possibly Damaging0.537Possibly Damaging4.23Benign0.81Tolerated3.61500-2.813.00
c.484C>GR162GLikely BenignUncertain 1-6.985Likely Benign0.664Likely PathogenicLikely Benign0.190Likely Benign-0.73Neutral0.487Possibly Damaging0.272Benign4.09Benign0.78Tolerated3.744-2-34.1-99.14
c.48G>AM16ILikely BenignUncertain 16-33420312-G-A16.49e-7-2.198Likely Benign0.722Likely PathogenicLikely Benign0.057Likely Benign-0.15Neutral0.000Benign0.000Benign4.28Benign0.00Affected4.321212.6-18.03
c.502C>TH168YLikely BenignBenign 1-8.914Likely Pathogenic0.264Likely BenignLikely Benign0.065Likely Benign-1.53Neutral0.192Benign0.062Benign4.18Benign0.01Affected4.323021.926.03
c.50C>TS17FLikely BenignUncertain 16-33420314-C-T106.49e-6-3.888Likely Benign0.637Likely PathogenicLikely Benign0.048Likely Benign-0.99Neutral0.486Possibly Damaging0.032Benign3.99Benign0.00Affected4.321-2-33.660.10
c.526A>CS176RLikely BenignUncertain 1-6.492Likely Benign0.987Likely PathogenicLikely Pathogenic0.247Likely Benign0.94Neutral0.718Possibly Damaging0.168Benign4.16Benign0.87Tolerated0-1-3.769.11
c.53A>GY18CLikely BenignUncertain 16-33420317-A-G442.88e-5-2.658Likely Benign0.251Likely BenignLikely Benign0.102Likely Benign-0.56Neutral0.872Possibly Damaging0.206Benign4.04Benign0.00Affected4.3210-23.8-60.04
c.59C>GP20RLikely BenignUncertain 1-3.548Likely Benign0.434AmbiguousLikely Benign0.146Likely Benign-0.15Neutral0.972Probably Damaging0.804Possibly Damaging4.33Benign0.00Affected4.3210-2-2.959.07
c.59C>TP20LLikely BenignUncertain 3-3.289Likely Benign0.464AmbiguousLikely Benign0.100Likely Benign-0.44Neutral0.909Possibly Damaging0.713Possibly Damaging4.27Benign0.00Affected4.321-3-35.416.04
c.5G>AS2NLikely BenignUncertain 26-33420269-G-A31.96e-6-4.104Likely Benign0.207Likely BenignLikely Benign0.092Likely Benign-0.36Neutral0.000Benign0.000Benign4.06Benign0.00Affected4.32111-2.727.03
c.68A>GD23GLikely BenignUncertain 1-2.622Likely Benign0.684Likely PathogenicLikely Benign0.100Likely Benign-2.45Neutral0.805Possibly Damaging0.539Possibly Damaging3.50Benign0.00Affected1-13.1-58.04
c.70G>AV24ILikely BenignUncertain 16-33423479-G-A95.58e-6-3.701Likely Benign0.137Likely BenignLikely Benign0.069Likely Benign-0.25Neutral0.043Benign0.031Benign3.96Benign0.00Affected4.321340.314.03
c.603T>AD201E
(3D Viewer)
Likely BenignPHBenign 1-2.640Likely Benign0.406AmbiguousLikely Benign0.165Likely Benign0.42Likely Benign0.21.99Ambiguous1.21Ambiguous0.23Likely Benign-0.69Neutral0.633Possibly Damaging0.108Benign4.30Benign1.00Tolerated3.469320.014.03258.7-24.80.90.1-0.30.2XUncertainAsp201, an acidic residue located in the N-terminal loop before the first anti-parallel β sheet strand (res. Ile205-Pro208), is replaced by another acidic residue, glutamate. The carboxylate groups of both Asp201 and Glu201 side chains form hydrogen bonds with the hydroxyl group of Ser221 in the simulations. Due to its shorter side chain, Asp201 can also hydrogen bond with the backbone amide groups of neighboring loop residues Ser204 and Asp203. However, since the model ends abruptly at the N-terminus, no definite conclusions can be drawn from the simulations.
c.603T>GD201E
(3D Viewer)
Likely BenignPHConflicting 26-33435245-T-G201.24e-5-2.640Likely Benign0.406AmbiguousLikely Benign0.165Likely Benign0.42Likely Benign0.21.99Ambiguous1.21Ambiguous0.23Likely Benign-0.69Neutral0.633Possibly Damaging0.108Benign4.30Benign1.00Tolerated3.469320.014.03258.7-24.80.90.1-0.30.2XUncertainAsp201, an acidic residue located in the N-terminal loop before the first anti-parallel β sheet strand (res. Ile205-Pro208), is replaced by another acidic residue, glutamate. The carboxylate groups of both Asp201 and Glu201 side chains form hydrogen bonds with the hydroxyl group of Ser221 in the simulations. Due to its shorter side chain, Asp201 can also hydrogen bond with the backbone amide groups of neighboring loop residues Ser204 and Asp203. However, since the model ends abruptly at the N-terminus, no definite conclusions can be drawn from the simulations.
c.611C>GS204C
(3D Viewer)
Likely BenignPHUncertain 1-6.613Likely Benign0.127Likely BenignLikely Benign0.148Likely Benign0.65Ambiguous0.4-1.13Ambiguous-0.24Likely Benign0.10Likely Benign-0.64Neutral0.978Probably Damaging0.753Possibly Damaging4.13Benign0.05Affected3.44100-13.316.06223.6-13.80.60.30.00.2XUncertainThe hydroxyl-containing Ser204, located in the N-terminal loop before the first anti-parallel β sheet strand (res. Ile205-Pro208), is replaced by the thiol-containing cysteine. In the WT simulations, Ser204 simultaneously forms hydrogen bonds with the backbone carbonyl of Asp201 and the hydroxyl group of Thr224, helping to stabilize the two anti-parallel β strands (res. Ile205-Lys207 and Cys219-Thr223) at the end of the β sheet. Since the thiol group of cysteine forms weaker hydrogen bonds than the hydroxyl group of serine, Cys204 does not maintain the hydrogen bond network as stably as Ser204 in the variant simulations. However, because the model ends abruptly at the N-terminus, no definite conclusions can be drawn from the simulations.
c.73C>TR25WLikely BenignUncertain 26-33423482-C-T63.72e-6-5.133Likely Benign0.549AmbiguousLikely Benign0.158Likely Benign-1.60Neutral0.994Probably Damaging0.919Probably Damaging3.92Benign0.00Affected4.321-323.630.03
c.74G>AR25QLikely BenignUncertain 16-33423483-G-A159.29e-6-4.126Likely Benign0.212Likely BenignLikely Benign0.038Likely Benign-0.70Neutral0.829Possibly Damaging0.614Possibly Damaging4.01Benign0.00Affected4.321111.0-28.06
c.76G>AG26RLikely BenignBenign 16-33423485-G-A31.86e-6-2.946Likely Benign0.678Likely PathogenicLikely Benign0.189Likely Benign-2.22Neutral0.994Probably Damaging0.990Probably Damaging3.87Benign0.00Affected4.321-3-2-4.199.14
c.82T>CS28PLikely BenignUncertain 1-3.309Likely Benign0.051Likely BenignLikely Benign0.047Likely Benign1.37Neutral0.000Benign0.000Benign4.53Benign0.00Affected4.3211-1-0.810.04
c.866T>CM289TLikely BenignC2Uncertain1-4.668Likely Benign0.238Likely BenignLikely Benign0.222Likely Benign0.73Ambiguous0.10.17Likely Benign0.45Likely Benign-0.01Likely Benign-0.47Neutral0.801Possibly Damaging0.315Benign1.83Pathogenic0.57Tolerated-1-1-2.6-30.09
c.86T>CM29TLikely BenignUncertain 1-2.167Likely Benign0.122Likely BenignLikely Benign0.199Likely Benign-0.37Neutral0.018Benign0.184Benign4.33Benign0.00Affected4.321-1-1-2.6-30.09
c.88C>TH30YLikely BenignUncertain 1-3.047Likely Benign0.115Likely BenignLikely Benign0.082Likely Benign-1.84Neutral0.273Benign0.478Possibly Damaging3.99Benign0.00Affected4.321021.926.03
c.892C>TP298S
(3D Viewer)
Likely BenignC2Benign 16-33437797-C-T53.10e-6-6.342Likely Benign0.144Likely BenignLikely Benign0.189Likely Benign1.38Ambiguous0.21.41Ambiguous1.40Ambiguous0.58Ambiguous-1.20Neutral0.991Probably Damaging0.898Possibly Damaging2.03Pathogenic0.85Tolerated3.3920-110.8-10.04
c.745G>AA249T
(3D Viewer)
Likely BenignPHUncertain 1-3.564Likely Benign0.805Likely PathogenicAmbiguous0.487Likely Benign1.50Ambiguous0.61.39Ambiguous1.45Ambiguous0.30Likely Benign-0.96Neutral0.990Probably Damaging0.815Possibly Damaging5.65Benign0.40Tolerated3.391510-2.530.03214.5-43.30.00.00.50.2XPotentially BenignThe methyl group of Ala249, located on the surface of an α helix (res. Ala236-Val250) facing an anti-parallel β sheet strand (res. Ile205-Val209), packs against nearby hydrophobic residues such as Leu200, Leu246, and Val250. In the variant simulations, the hydroxyl group of Thr249, which is not suitable for hydrophobic packing, forms a stable hydrogen bond with the backbone carbonyl of Asn245 in the same helix. Although this interaction could theoretically weaken the structural integrity of the α helix, this destabilizing effect is not observed in the variant simulations.
c.92G>AR31QLikely BenignUncertain 16-33423501-G-A74.34e-6-4.434Likely Benign0.136Likely BenignLikely Benign0.051Likely Benign-0.92Neutral0.829Possibly Damaging0.614Possibly Damaging4.01Benign0.00Affected4.321111.0-28.06
c.958G>AV320I
(3D Viewer)
Likely BenignC2Uncertain 1-5.220Likely Benign0.111Likely BenignLikely Benign0.027Likely Benign-0.27Likely Benign0.20.66Ambiguous0.20Likely Benign0.01Likely Benign-0.21Neutral0.198Benign0.114Benign1.77Pathogenic0.45Tolerated3.3823340.314.03
c.971G>AR324Q
(3D Viewer)
Likely BenignC2Uncertain 36-33437876-G-A31.86e-6-5.001Likely Benign0.173Likely BenignLikely Benign0.307Likely Benign0.56Ambiguous0.10.63Ambiguous0.60Ambiguous1.02Destabilizing-1.17Neutral0.999Probably Damaging0.994Probably Damaging1.92Pathogenic0.41Tolerated3.3922111.0-28.06
c.819G>TE273D
(3D Viewer)
Likely BenignC2Benign 16-33437724-G-T21.24e-6-1.811Likely Benign0.058Likely BenignLikely Benign0.092Likely Benign0.26Likely Benign0.1-0.48Likely Benign-0.11Likely Benign-0.63Ambiguous1.99Neutral0.004Benign0.010Benign2.00Pathogenic1.00Tolerated3.3818320.0-14.03223.122.10.20.00.00.1XPotentially BenignThe negatively charged residue Glu273, located in a β hairpin loop (res. Glu273-Lys278) that connects two anti-parallel β sheet strands, is replaced with another negatively charged residue, aspartate. Because the C2 domain loop faces the membrane surface, the potentially crucial role of the carboxylate group of Glu273 or Asp273 on SynGAP-membrane association cannot be fully explored via solvent-only simulations.As a minor note, the neighboring residue Arg272, which stacks with the indole ring of the Trp362 side chain and directly faces RasGTPase, forms a salt bridge more often with Asp273 than with the non-mutated Glu273 in the simulations. Regardless, due to the similar physicochemical properties of the WT and variant residues at the membrane interface, the residue swap is likely to be well tolerated.
c.865A>GM289V
(3D Viewer)
Likely BenignC2Benign 1-4.239Likely Benign0.117Likely BenignLikely Benign0.150Likely Benign1.09Ambiguous0.1-0.27Likely Benign0.41Likely Benign0.24Likely Benign-0.36Neutral0.136Benign0.054Benign1.80Pathogenic1.00Tolerated3.3823212.3-32.06204.251.00.00.00.20.0XPotentially BenignThe hydrophobic residue Met289, located in a β hairpin linking two anti-parallel β sheet strands (res. Met289-Arg299, res. Arg272-Leu286), is swapped for another hydrophobic residue, valine. In the variant simulations, the branched hydrocarbon side chain of Val289 packs against the phenol group of the Tyr291 side chain but is unable to form methionine-aromatic interactions. β hairpins are potential nucleation sites during the initial stages of protein folding, so even minor changes in them could be significant. However, based on the simulations, the residue swap does not cause adverse effects on the structure.
c.886T>GS296A
(3D Viewer)
Likely BenignC2Uncertain 1-6.847Likely Benign0.247Likely BenignLikely Benign0.209Likely Benign0.50Ambiguous0.3-0.26Likely Benign0.12Likely Benign0.35Likely Benign-1.79Neutral0.992Probably Damaging0.987Probably Damaging1.97Pathogenic0.65Tolerated3.4016112.6-16.00182.526.6-0.20.1-0.50.0XPotentially PathogenicThe hydroxyl group of the Ser296 side chain, located in an anti-parallel β sheet strand (res. Met289-Pro298), stably hydrogen bonds with the carboxylate group of Asp330 in a neighboring β strand (res. Ala322-Asp332). The backbone carbonyl group of Ser296 also hydrogen bonds with the guanidinium group of Arg279 in another nearby β strand (res. Arg279-Cys285). In the variant simulations, the methyl group of the Ala296 side chain cannot hydrogen bond with Asp330, causing the carboxylate group positioning to fluctuate more than in the WT simulations.Although the residue swap does not seem to affect the anti-parallel β sheet assembly during the simulations, it is possible that the Ser296-Asp330 hydrogen bond plays a crucial role in maintaining the C2 domain fold. Notably, because Ser296 is located near the membrane interface, the potential effect of the residue swap on the SynGAP-membrane association cannot be addressed by solvent-only simulations.
c.901G>AA301T
(3D Viewer)
Likely BenignC2Uncertain 56-33437806-G-A21.24e-6-3.448Likely Benign0.070Likely BenignLikely Benign0.150Likely Benign0.36Likely Benign0.2-0.33Likely Benign0.02Likely Benign0.03Likely Benign-0.25Neutral0.997Probably Damaging0.989Probably Damaging4.15Benign0.22Tolerated4.321410-2.530.03219.8-42.8-0.10.0-0.50.2UncertainThe methyl group of Ala301, located in a β hairpin loop linking two anti-parallel β sheet strands (res. Met289-Pro298, res. Thr305-Asn315), points outward from the β hairpin loop, and its backbone atoms do not participate in the loop formation in the WT simulations. In the variant simulations, the hydroxyl group of the Thr301 side chain also mostly points outward; however, the guanidinium group of Arg299 is moved away from its central hairpin loop position.β hairpins are potential nucleation sites during the initial stages of protein folding, so even minor changes in them could be significant. Due to its location near the membrane surface, the residue swap could also affect the C2 loop dynamics and SynGAP-membrane association. However, this is beyond the scope of the solvent-only simulations to unravel.
c.913A>GT305A
(3D Viewer)
Likely BenignC2Conflicting 26-33437818-A-G138.05e-6-4.307Likely Benign0.078Likely BenignLikely Benign0.144Likely Benign1.30Ambiguous0.61.55Ambiguous1.43Ambiguous0.77Ambiguous-2.10Neutral0.939Possibly Damaging0.645Possibly Damaging1.76Pathogenic0.12Tolerated3.4020102.5-30.03177.943.5-0.20.10.40.0UncertainThe hydroxyl group of Thr305, located at the beginning of an anti-parallel β strand (res. Thr305-Asn315), hydrogen bonds with the carboxylate groups of Glu270 and Asp304 in the anti-parallel β strand and the adjacent β hairpin loop, respectively. In the variant simulations, the methyl group of the Ala305 side chain cannot hydrogen bond with either of the acidic residues, which could weaken the integrity of the tertiary structure and the β hairpin loop. Indeed, the guanidinium group of Arg299 does not acquire its central hairpin loop position due to the residue swap.β hairpins are potential nucleation sites during the initial stages of protein folding, so even minor changes in them could be significant. Due to its location near the membrane surface, the residue swap could also affect the C2 loop dynamics and SynGAP-membrane association. However, this is beyond the scope of the solvent-only simulations to unravel.
c.1003C>TR335C
(3D Viewer)
Likely PathogenicC2Uncertain 16-33437908-C-T16.20e-7-14.354Likely Pathogenic0.938Likely PathogenicAmbiguous0.277Likely Benign0.53Ambiguous0.10.85Ambiguous0.69Ambiguous0.46Likely Benign-5.69Deleterious1.000Probably Damaging0.998Probably Damaging1.67Pathogenic0.01Affected3.3822-3-47.0-53.05
c.1004G>AR335H
(3D Viewer)
Likely PathogenicC2Uncertain 16-33437909-G-A21.24e-6-12.521Likely Pathogenic0.831Likely PathogenicAmbiguous0.132Likely Benign0.58Ambiguous0.10.22Likely Benign0.40Likely Benign0.72Ambiguous-3.02Deleterious1.000Probably Damaging0.998Probably Damaging1.70Pathogenic0.03Affected3.3822201.3-19.05242.482.1-2.40.6-0.10.1UncertainThe guanidinium group of Arg335, located in a β hairpin loop linking two anti-parallel β sheet strands (res. Ala322-Asp330, res. Gly341-Pro349), faces the post-synaptic inner membrane surface. In the WT simulations, the Arg335 side chain dynamically forms salt bridges with the carboxylate groups of Asp322, Asp338, and Asp616. In contrast, the imidazole ring of His335, which is not double protonated and thus not positively charged in the variant simulations, continues to move dynamically without forming any lasting or strong interactions. Importantly, the positively charged arginine residues of the C2 domain are ideal membrane anchors for ensuring SynGAP-membrane association. However, this phenomenon cannot be addressed using solvent-only simulations.
c.1025A>CY342S
(3D Viewer)
Likely PathogenicC2Uncertain 2-7.996In-Between0.925Likely PathogenicAmbiguous0.407Likely Benign3.03Destabilizing0.12.87Destabilizing2.95Destabilizing0.93Ambiguous-6.60Deleterious1.000Probably Damaging0.998Probably Damaging1.75Pathogenic0.04Affected3.3725-3-20.5-76.10200.177.80.00.0-0.20.1Potentially PathogenicThe phenol ring of Tyr342, located at the end of an anti-parallel β sheet strand (res. Gly341-Pro349), faces outward in the C2 domain. In the WT simulations, the phenol ring of Tyr342 contributes to a triple tyrosine stack (Tyr342, Tyr328, and Tyr281) that links together three anti-parallel β sheet strands. Additionally, it shields Gly344 from the solvent, reducing its exposure and providing stability for the β-sandwich. This motif also contributes to a twist formation in the β sheet.In the variant simulations, the Ser342 side chain cannot participate in the stack formation. Instead, the hydroxyl group of the Ser342 side chain forms a hydrogen bond with the imidazole ring of His326 in a neighboring β strand (res. Ala322-Asp330). This disrupts the formation of a hydrogen bond between His326 and the carboxylate group of the Glu283 side chain from another β strand (res. Arg279-Cys285). Although these changes in surface interactions could weaken the characteristic twist that strengthens the β sheet fold, no major structural effects are observed in the variant simulations. The residue swap could also affect the SynGAP-membrane association, as the hydroxyl group of Ser342 could form hydrogen bonds with membrane-facing loop residues. However, this phenomenon cannot be addressed using solvent-only simulations.
c.1025A>GY342C
(3D Viewer)
Likely PathogenicC2Benign/Likely benign 26-33437930-A-G211.30e-5-7.596In-Between0.682Likely PathogenicLikely Benign0.404Likely Benign2.48Destabilizing0.12.73Destabilizing2.61Destabilizing0.92Ambiguous-6.67Deleterious1.000Probably Damaging0.999Probably Damaging1.72Pathogenic0.02Affected3.37250-23.8-60.04242.462.80.10.0-0.10.2Potentially PathogenicThe phenol ring of Tyr342, located at the end of an anti-parallel β sheet strand (res. Gly341-Pro349), faces outward in the C2 domain. This phenol ring contributes to a triple tyrosine stack (Tyr342, Tyr328, and Tyr281) that links together three anti-parallel β sheet strands. Additionally, it shields Gly344 from the solvent, reducing its exposure and providing stability for the β-sandwich. This motif also contributes to a twist formation in the β sheet.In the variant simulations, the Cys342 side chain cannot participate in the stack formation. Instead, its thiol group forms a hydrogen bond with the backbone carbonyl group of Leu327. Although these changes in surface interactions could weaken the characteristic twist that strengthens the β sheet fold, no major structural effects are observed in the variant simulations. The residue swap could also affect the SynGAP-membrane association; however, this phenomenon cannot be addressed using solvent-only simulations. Notably, the thiol group of cysteine is not a particularly strong hydrogen-bonding partner, which could mitigate the negative effects of the residue swap.
c.1058T>CL353P
(3D Viewer)
Likely PathogenicC2Uncertain 1-7.913In-Between0.936Likely PathogenicAmbiguous0.464Likely Benign4.63Destabilizing0.110.19Destabilizing7.41Destabilizing2.17Destabilizing-3.70Deleterious0.947Possibly Damaging0.454Possibly Damaging1.29Pathogenic0.02Affected3.3725-3-3-5.4-16.04
c.1067G>AR356H
(3D Viewer)
Likely PathogenicC2Likely Benign 16-33437972-G-A95.66e-6-11.453Likely Pathogenic0.614Likely PathogenicLikely Benign0.314Likely Benign0.59Ambiguous0.1-0.27Likely Benign0.16Likely Benign1.17Destabilizing-4.43Deleterious0.999Probably Damaging0.987Probably Damaging1.70Pathogenic0.01Affected3.3922021.3-19.05
c.1082A>CQ361P
(3D Viewer)
Likely PathogenicC2Likely Pathogenic 1-13.280Likely Pathogenic0.956Likely PathogenicLikely Pathogenic0.482Likely Benign3.12Destabilizing0.03.45Destabilizing3.29Destabilizing0.38Likely Benign-3.03Deleterious0.996Probably Damaging0.979Probably Damaging1.63Pathogenic0.05Affected3.3725-101.9-31.01
c.1030G>AG344S
(3D Viewer)
Likely PathogenicC2Pathogenic 5-11.254Likely Pathogenic0.986Likely PathogenicLikely Pathogenic0.790Likely Pathogenic9.02Destabilizing0.76.08Destabilizing7.55Destabilizing0.98Ambiguous-5.28Deleterious1.000Probably Damaging1.000Probably Damaging-0.45Pathogenic0.04Affected3.372510-0.430.03217.3-51.70.00.10.20.1XXPotentially PathogenicBecause Gly344 lacks a proper side chain, it allows the anti-parallel β sheet strand (res. Gly341-Pro349) to have a slight twist. Within a β strand, side chains normally alternate between outward and inward positions, but glycine is an exception as it allows the alternating pattern to skip a residue. Introducing serine or any other residue with a side chain at position 344 prevents this unique skip in the alternating pattern, causing structural strain or likely preventing correct folding altogether. Additionally, Tyr342 shields Gly344 from the solvent, contributing to twist formation in the β sheet and stabilizing the β-strand.In the variant simulations, the side chain of Ser344 assumes the inward position. However, the hydrophobic niche formed by multiple C2 domain residues (e.g., Val365, Val343, Leu327) is not accommodating for its hydroxyl group. The outward position, not seen in the simulations, would be equally disadvantageous due to the presence of hydrophobic residues on that side as well (e.g., Leu345, Tyr342). Serine is also not well-suited for twist formation, as it tends to suppress twisting and bending in β sheets. At this position, the hydroxyl group of Ser344 could also form hydrogen bonds with the backbone atoms of the Gly-rich Ω loop in the C2 domain (e.g., Thr366, Leu367, Gly378; res. Pro364-Pro398), potentially adversely affecting membrane-loop dynamics and ultimately compromising the stability of the SynGAP-membrane association.
c.1202G>AR401Q
(3D Viewer)
Likely PathogenicC2Uncertain 16-33438107-G-A-11.213Likely Pathogenic0.969Likely PathogenicLikely Pathogenic0.780Likely Pathogenic0.96Ambiguous0.11.50Ambiguous1.23Ambiguous1.20Destabilizing-3.69Deleterious0.999Probably Damaging0.978Probably Damaging5.47Benign0.04Affected3.3827111.0-28.06
c.1214G>CR405P
(3D Viewer)
Likely PathogenicC2Uncertain 1-14.206Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.572Likely Pathogenic3.11Destabilizing0.35.19Destabilizing4.15Destabilizing1.26Destabilizing-6.32Deleterious1.000Probably Damaging1.000Probably Damaging3.62Benign0.01Affected3.3828-202.9-59.07
c.1221G>TQ407H
(3D Viewer)
Likely PathogenicC2Uncertain 1-10.526Likely Pathogenic0.830Likely PathogenicAmbiguous0.206Likely Benign0.59Ambiguous0.00.61Ambiguous0.60Ambiguous1.10Destabilizing-4.51Deleterious0.982Probably Damaging0.947Probably Damaging3.88Benign0.01Affected3.3828030.39.01
c.1066C>TR356C
(3D Viewer)
Likely PathogenicC2Likely Benign 16-33437971-C-T53.10e-6-11.827Likely Pathogenic0.774Likely PathogenicLikely Benign0.312Likely Benign0.76Ambiguous0.01.19Ambiguous0.98Ambiguous0.84Ambiguous-7.12Deleterious1.000Probably Damaging0.990Probably Damaging1.67Pathogenic0.00Affected3.3922-4-37.0-53.05212.391.0-0.10.3-0.30.1XPotentially PathogenicArg356 is located in a loop that includes a short helical section and connects two anti-parallel β sheet strands (res. Gly341-Pro349, res. Thr359-Pro364). In the WT simulations, the guanidinium group of Arg356 alternately forms salt bridges with the carboxylate groups of the GAP domain residues, Glu446 and Glu698. Arg356 also forms hydrogen bonds with the hydroxyl group of the GAP domain residue Thr691 and interacts with Met409 at the C2-GAP interface.In the variant simulations, the Cys356 mutation fails to maintain any of the Arg356 interactions and only occasionally forms weak hydrogen bonds with nearby C2 domain residues (e.g., Gln407). Although no negative structural effects are observed during the simulations, Arg356 is located at the C2 and GAP domain interface, making the residue swap potentially detrimental to the tertiary structure assembly.
c.1084T>CW362R
(3D Viewer)
Likely PathogenicC2Pathogenic 2-14.004Likely Pathogenic1.000Likely PathogenicLikely Pathogenic0.706Likely Pathogenic2.64Destabilizing0.33.90Destabilizing3.27Destabilizing1.10Destabilizing-12.87Deleterious0.999Probably Damaging0.996Probably Damaging1.28Pathogenic0.00Affected3.39242-3-3.6-30.03287.5-34.1-0.20.1-0.60.2XXXPotentially PathogenicThe indole ring of Trp362, located on the surface of an anti-parallel β sheet (res. Thr359-Pro364) in the C2 domain, stacks with nearby residues (e.g., Arg401, Arg272). In the variant simulations, the guanidinium group of the introduced residue Arg362 forms a salt bridge with the carboxylate group of Glu273 and, like Trp362, stacks with other arginine residues (e.g., Arg401, Arg272). This residue is at both the C2-membrane interface and the C2-RasGTPase interface, so the residue swap could potentially affect both interactions. However, these phenomena cannot be addressed using solvent-only simulations. Notably, Arg272, which stacks with both the non-mutated Trp362 and the mutated Arg362, forms a salt bridge directly with Asp105 of Ras in the WT simulations. Therefore, the residue swap could affect the C2 domain stability, the SynGAP-membrane association, and the SynGAP-Ras association.10.1016/j.ajhg.2020.11.011
c.1352T>CL451P
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-14.549Likely Pathogenic1.000Likely PathogenicLikely Pathogenic0.750Likely Pathogenic6.92Destabilizing0.28.57Destabilizing7.75Destabilizing2.58Destabilizing-6.81Deleterious1.000Probably Damaging1.000Probably Damaging2.43Pathogenic0.00Affected3.3734-3-3-5.4-16.04
c.1367A>CQ456P
(3D Viewer)
Likely PathogenicGAPUncertain 1-15.250Likely Pathogenic0.993Likely PathogenicLikely Pathogenic0.469Likely Benign3.68Destabilizing0.28.43Destabilizing6.06Destabilizing0.82Ambiguous-5.66Deleterious1.000Probably Damaging0.999Probably Damaging3.34Benign0.07Tolerated3.3734-101.9-31.01
c.1370G>AS457NLikely PathogenicGAPUncertain 1-10.221Likely Pathogenic0.949Likely PathogenicAmbiguous0.241Likely Benign0.19Likely Benign0.0-0.22Likely Benign-0.02Likely Benign0.67Ambiguous-2.76Deleterious0.940Possibly Damaging0.843Possibly Damaging3.28Benign0.06Tolerated11-2.727.03
c.1404G>AM468I
(3D Viewer)
Likely PathogenicGAPUncertain 16-33438436-G-A16.20e-7-8.583Likely Pathogenic0.907Likely PathogenicAmbiguous0.508Likely Pathogenic2.53Destabilizing0.21.89Ambiguous2.21Destabilizing0.37Likely Benign-1.06Neutral0.748Possibly Damaging0.886Possibly Damaging-1.10Pathogenic0.07Tolerated3.3731122.6-18.03
c.1405G>AA469T
(3D Viewer)
Likely PathogenicGAPUncertain 1-9.540Likely Pathogenic0.723Likely PathogenicLikely Benign0.527Likely Pathogenic2.26Destabilizing0.11.90Ambiguous2.08Destabilizing0.34Likely Benign-1.46Neutral0.994Probably Damaging0.986Probably Damaging-1.21Pathogenic0.42Tolerated10-2.530.03
c.1408A>GM470V
(3D Viewer)
Likely PathogenicGAPUncertain 1-8.856Likely Pathogenic0.478AmbiguousLikely Benign0.770Likely Pathogenic2.73Destabilizing0.11.88Ambiguous2.31Destabilizing1.31Destabilizing-3.58Deleterious0.999Probably Damaging0.993Probably Damaging-1.20Pathogenic0.15Tolerated3.3734122.3-32.06
c.1453C>AR485S
(3D Viewer)
Likely PathogenicGAPUncertain 1-15.603Likely Pathogenic0.998Likely PathogenicLikely Pathogenic0.609Likely Pathogenic0.40Likely Benign0.11.07Ambiguous0.74Ambiguous0.82Ambiguous-5.97Deleterious1.000Probably Damaging1.000Probably Damaging1.93Pathogenic0.00Affected0-13.7-69.11
c.1454G>AR485H
(3D Viewer)
Likely PathogenicGAPLikely Benign 16-33438486-G-A138.05e-6-13.628Likely Pathogenic0.948Likely PathogenicAmbiguous0.618Likely Pathogenic0.77Ambiguous0.10.12Likely Benign0.45Likely Benign1.13Destabilizing-4.97Deleterious1.000Probably Damaging0.998Probably Damaging1.93Pathogenic0.00Affected3.3735021.3-19.05
c.1463C>TT488M
(3D Viewer)
Likely PathogenicGAPUncertain 16-33438495-C-T21.24e-6-12.459Likely Pathogenic0.973Likely PathogenicLikely Pathogenic0.746Likely Pathogenic0.66Ambiguous0.31.62Ambiguous1.14Ambiguous0.46Likely Benign-5.70Deleterious1.000Probably Damaging0.999Probably Damaging3.21Benign0.00Affected3.3735-1-12.630.09
c.1468G>CA490P
(3D Viewer)
Likely PathogenicGAPUncertain 1-12.905Likely Pathogenic0.941Likely PathogenicAmbiguous0.878Likely Pathogenic-1.27Ambiguous0.11.31Ambiguous0.02Likely Benign1.07Destabilizing-4.81Deleterious1.000Probably Damaging0.998Probably Damaging-1.42Pathogenic0.01Affected3.3735-11-3.426.04
c.1474A>GK492E
(3D Viewer)
Likely PathogenicGAPConflicting 2-16.175Likely Pathogenic0.998Likely PathogenicLikely Pathogenic0.510Likely Pathogenic1.53Ambiguous0.11.90Ambiguous1.72Ambiguous1.42Destabilizing-3.98Deleterious1.000Probably Damaging0.998Probably Damaging2.99Benign0.01Affected3.3735100.40.94
c.1199T>AV400E
(3D Viewer)
Likely PathogenicC2Uncertain 1-13.686Likely Pathogenic0.998Likely PathogenicLikely Pathogenic0.810Likely Pathogenic3.70Destabilizing0.22.46Destabilizing3.08Destabilizing2.29Destabilizing-4.88Deleterious0.920Possibly Damaging0.335Benign5.31Benign0.00Affected3.3827-2-2-7.729.98249.1-38.8-0.10.11.00.0XXXPotentially PathogenicThe iso-propyl side chain of Val400, located in an anti-parallel β sheet strand (res. Ala399-Ile411), hydrophobically packs against hydrophobic residues within the anti-parallel β sheet of the C2 domain (e.g., Ile268, Ala404, Leu325, Leu402). In the variant simulations, the negatively charged carboxylate group of the Glu400 side chain is not suitable for occupying the hydrophobic niche. Consequently, the side chain escapes the center of the C2 domain and interacts with the backbone amide groups of Leu402 in the same β strand and/or Ile269 and Glu270 in a neighboring β strand (res. Arg259-Arg272). This residue swap disrupts the hydrophobic packing and generally has extensive negative effects on the C2 domain structure. At a minimum, the residue swap could affect the C2 domain stability and membrane association.
c.1205T>GL402R
(3D Viewer)
Likely PathogenicC2Likely Pathogenic1-13.800Likely Pathogenic0.997Likely PathogenicLikely Pathogenic0.522Likely Pathogenic4.10Destabilizing0.23.82Destabilizing3.96Destabilizing2.24Destabilizing-4.69Deleterious0.967Probably Damaging0.459Possibly Damaging3.69Benign0.00Affected3.3828-3-2-8.343.03259.5-55.40.00.01.40.0XXXPotentially PathogenicThe iso-butyl side chain of Leu402, located in an anti-parallel β sheet strand (res. Ala399-Ile411), packs with residues inside the hydrophobic core of the C2 domain (e.g., Ile268, Ala404, Leu266, Val400). In the variant simulations, the positively charged guanidinium group of the Arg402 side chain is not suitable for the hydrophobic niche. Consequently, the side chain moves outward from the hydrophobic C2 domain core and stacks with the phenol ring of Tyr363 or forms H-bonds with the carboxamide group of the Gln361 side chain in the β sheet strand (res. Thr359-Tyr364). This movement induces extensive negative effects on the C2 domain structure.
c.1213C>TR405C
(3D Viewer)
Likely PathogenicC2Conflicting 26-33438118-C-T63.72e-6-9.206Likely Pathogenic0.713Likely PathogenicLikely Benign0.427Likely Benign0.72Ambiguous0.11.51Ambiguous1.12Ambiguous1.21Destabilizing-7.27Deleterious1.000Probably Damaging1.000Probably Damaging3.61Benign0.02Affected3.3828-4-37.0-53.05221.382.6-0.10.0-0.20.3XXPotentially PathogenicThe guanidinium group of Arg405, located in an anti-parallel β sheet strand of the C2 domain (res. Ala399-Ile411), forms a salt bridge with the carboxylate group of the Glu446 side chain from an opposing α helix (res. Val441-Ser457) in the GAP domain. The positively charged Arg405 side chain also stacks with the aromatic ring of the Phe358 side chain from a loop preceding the β strand (res. Thr359-Thr366), which could assist in maintaining the anti-parallel strand arrangement.In the variant simulations, the thiol-containing side chain of Cys405 is neutral and smaller compared to the arginine side chain. The lack of Arg405-Phe358 stacking affects the loop structure, causing it to assume a β strand form—an effect that could be exacerbated during protein folding. Moreover, the inability of Cys405 to form a salt bridge with Glu446 could affect the tertiary structure assembly, although this is not apparent based on the variant simulations.
c.1483G>AE495K
(3D Viewer)
Likely PathogenicGAPUncertain 1-11.478Likely Pathogenic0.986Likely PathogenicLikely Pathogenic0.869Likely Pathogenic0.15Likely Benign0.20.66Ambiguous0.41Likely Benign0.70Ambiguous-3.91Deleterious0.999Probably Damaging0.994Probably Damaging-1.29Pathogenic0.01Affected3.373510-0.4-0.94
c.1499T>CL500P
(3D Viewer)
Likely PathogenicGAPPathogenic 1-15.898Likely Pathogenic0.996Likely PathogenicLikely Pathogenic0.894Likely Pathogenic5.91Destabilizing0.38.90Destabilizing7.41Destabilizing1.92Destabilizing-6.96Deleterious1.000Probably Damaging1.000Probably Damaging-1.37Pathogenic0.01Affected3.3735-3-3-5.4-16.04
c.1513T>CY505H
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-11.383Likely Pathogenic0.982Likely PathogenicLikely Pathogenic0.646Likely Pathogenic2.91Destabilizing0.12.88Destabilizing2.90Destabilizing1.60Destabilizing-4.97Deleterious1.000Probably Damaging1.000Probably Damaging2.64Benign0.00Affected3.373520-1.9-26.03
c.1513T>GY505D
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-14.078Likely Pathogenic0.993Likely PathogenicLikely Pathogenic0.718Likely Pathogenic4.98Destabilizing0.14.72Destabilizing4.85Destabilizing2.49Destabilizing-9.95Deleterious1.000Probably Damaging1.000Probably Damaging2.60Benign0.00Affected3.3735-3-4-2.2-48.09
c.1516C>TL506F
(3D Viewer)
Likely PathogenicGAPUncertain 1-11.262Likely Pathogenic0.883Likely PathogenicAmbiguous0.464Likely Benign4.92Destabilizing0.85.76Destabilizing5.34Destabilizing0.91Ambiguous-3.98Deleterious0.999Probably Damaging0.997Probably Damaging1.62Pathogenic0.01Affected3.373502-1.034.02
c.1540A>TI514F
(3D Viewer)
Likely PathogenicGAPUncertain 1-13.383Likely Pathogenic0.962Likely PathogenicLikely Pathogenic0.601Likely Pathogenic2.35Destabilizing0.33.74Destabilizing3.05Destabilizing0.93Ambiguous-3.98Deleterious0.997Probably Damaging0.993Probably Damaging2.89Benign0.00Affected3.373501-1.734.02
c.1214G>AR405H
(3D Viewer)
Likely PathogenicC2Conflicting 26-33438119-G-A42.48e-6-9.081Likely Pathogenic0.706Likely PathogenicLikely Benign0.371Likely Benign2.79Destabilizing0.61.85Ambiguous2.32Destabilizing1.26Destabilizing-4.54Deleterious1.000Probably Damaging0.991Probably Damaging3.65Benign0.01Affected3.3828201.3-19.05214.0102.2-0.10.0-0.70.1XPotentially PathogenicThe guanidinium group of Arg405, located in an anti-parallel β sheet strand of the C2 domain (res. Pro398-Ile411), forms a salt bridge with the carboxylate group of the Glu446 side chain from an opposing α helix (res. Val441-Ser457) in the GAP domain. The positively charged Arg405 side chain also stacks with the aromatic ring of the Phe358 side chain from a loop preceding the β strand (res. Thr359-Thr366), which could assist in maintaining the anti-parallel strand arrangement.In the variant simulations, the imidazole ring of His405 does not stack with the aromatic ring of Phe358 nor form any lasting H-bonds with the loop residues. The imidazole ring of His405 (neutral and epsilon protonated in the simulations) is unable to form a salt bridge with Glu446, which could affect the tertiary structure assembly, although this is not apparent based on the variant simulations.
c.1256A>GE419G
(3D Viewer)
Likely PathogenicGAPUncertain 1-10.589Likely Pathogenic0.956Likely PathogenicLikely Pathogenic0.469Likely Benign1.41Ambiguous0.01.94Ambiguous1.68Ambiguous0.83Ambiguous-6.42Deleterious1.000Probably Damaging0.997Probably Damaging3.31Benign0.02Affected3.37290-23.1-72.06165.3110.80.00.0-0.10.0XPotentially PathogenicThe carboxylate group of Glu419, located on an α helix (res. Met414-Glu436), forms a salt bridge with the side chain of either Arg716 or Lys418 from an opposing helix (res. Pro713-Arg726). The backbone amide group of Glu419 does not form H-bonds, resulting in a slight bend in the α helix. Thus, although glycine is known as an “α helix breaker,” the residue swap does not disrupt the continuity or integrity of the α helix. However, because Gly419 cannot form a salt bridge with the guanidinium group of the Arg716 side chain, the C2-GAP domain tertiary structure could be compromised during folding.
c.1259T>CF420S
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-13.231Likely Pathogenic1.000Likely PathogenicLikely Pathogenic0.544Likely Pathogenic5.34Destabilizing0.15.73Destabilizing5.54Destabilizing2.14Destabilizing-7.43Deleterious0.998Probably Damaging0.938Probably Damaging3.09Benign0.00Affected3.3729-3-2-3.6-60.10213.357.80.00.0-0.40.1XPotentially PathogenicIn the WT, the phenyl ring of the Phe420 side chain, located on an α helix (res. Met414-Glu436), packs against hydrophobic residues in the interhelix area of the GAP domain (e.g., Leu689, Leu714, Leu717, Leu718). Although no large-scale adverse effects are seen in the variant simulations, the polar hydroxyl group of Ser420 is not suitable for the hydrophobic inter-helix space. Thus, the residue swap could affect protein folding. In theory, the introduced hydroxyl group could also lower the α helix integrity by H-bonding with the backbone atoms of neighboring residues in the same α helix. However, no such effect is seen in the variant simulations.
c.1260T>GF420L
(3D Viewer)
Likely PathogenicGAPUncertain 1-8.432Likely Pathogenic0.998Likely PathogenicLikely Pathogenic0.146Likely Benign1.76Ambiguous0.01.41Ambiguous1.59Ambiguous1.04Destabilizing-5.39Deleterious0.009Benign0.005Benign4.22Benign0.39Tolerated3.3729201.0-34.02231.113.20.00.0-0.10.0XPotentially BenignIn the WT, the phenyl ring of the Phe420 side chain, located on an α helix (res. Met414-Glu436), packs against hydrophobic residues in the interhelix area of the GAP domain (e.g., Leu689, Leu714, Leu717, Leu718). In the variant simulations, the iso-butyl side chain of Leu420 also packs into the hydrophobic inter-helix niche, but due to its smaller size, the resulting steric interactions are not as favorable as with phenylalanine. In short, the residue swap does not cause severe effects on the protein structure based on the variant simulations.
c.1552T>CY518H
(3D Viewer)
Likely PathogenicGAPUncertain 1-9.797Likely Pathogenic0.943Likely PathogenicAmbiguous0.496Likely Benign2.39Destabilizing0.40.82Ambiguous1.61Ambiguous1.31Destabilizing-4.74Deleterious1.000Probably Damaging1.000Probably Damaging3.40Benign0.08Tolerated02-1.9-26.03
c.1558T>CS520P
(3D Viewer)
Likely PathogenicGAPUncertain 1-12.707Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.855Likely Pathogenic3.72Destabilizing0.88.86Destabilizing6.29Destabilizing0.83Ambiguous-4.57Deleterious0.997Probably Damaging0.986Probably Damaging-1.32Pathogenic0.01Affected1-1-0.810.04
c.1559C>TS520F
(3D Viewer)
Likely PathogenicGAPUncertain 1-12.541Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.833Likely Pathogenic-1.20Ambiguous0.40.39Likely Benign-0.41Likely Benign0.25Likely Benign-5.57Deleterious0.999Probably Damaging0.996Probably Damaging-1.36Pathogenic0.00Affected3.3735-2-33.660.10
c.1606T>GL536V
(3D Viewer)
Likely PathogenicGAPUncertain 1-9.014Likely Pathogenic0.269Likely BenignLikely Benign0.586Likely Pathogenic1.25Ambiguous0.31.22Ambiguous1.24Ambiguous1.20Destabilizing-2.81Deleterious0.998Probably Damaging0.992Probably Damaging-1.34Pathogenic0.09Tolerated3.3734210.4-14.03204.726.40.20.0-0.20.2XPotentially BenignLeu536 is located on an α-helix (res. Ala533-Val560) at the membrane interface. The iso-butyl group of Leu536 interacts with nearby hydrophobic residues in the preceding loop (e.g., Val526, Pro528, Cys531). In the variant simulations, the iso-propyl side chain of Val536 forms similar hydrophobic interactions as Leu536 in the WT, causing no negative structural effects.
c.1292T>CL431P
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-14.222Likely Pathogenic0.996Likely PathogenicLikely Pathogenic0.659Likely Pathogenic6.78Destabilizing0.311.59Destabilizing9.19Destabilizing2.29Destabilizing-6.39Deleterious1.000Probably Damaging0.998Probably Damaging2.91Benign0.05Affected3.3729-3-3-5.4-16.04222.462.80.10.00.10.0XPotentially PathogenicThe iso-butyl side chain of Leu431, located in an α helix (res. Met414-Glu436), packs against other hydrophobic residues in an interhelix space (e.g., Val434, Leu435, Leu696, Leu711) in the WT simulations. While the backbone amide group of Leu431 forms an H-bond with the carbonyl group of His427, the cyclic five-membered pyrrolidine ring of Pro431, lacking the necessary amide group, cannot do the same. Thus, although the cyclic five-membered pyrrolidine ring of Pro431 packs almost as favorably as the side chain of Leu431 in the hydrophobic niche, the residue swap causes the α helix to partially unfold in the variant simulations.
c.1304T>GL435W
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.889Likely Pathogenic0.992Likely PathogenicLikely Pathogenic0.572Likely Pathogenic2.11Destabilizing0.10.69Ambiguous1.40Ambiguous1.66Destabilizing-5.63Deleterious1.000Probably Damaging0.998Probably Damaging3.15Benign0.00Affected3.3729-2-2-4.773.05242.2-25.20.00.00.30.1XPotentially PathogenicThe iso-butyl side chain of Leu435, located in an α helix (res. Met414-Glu436), packs against other hydrophobic residues in an interhelix space (e.g., Val699, Val447, Leu489, Leu439) in the WT simulations. In the variant simulations, the indole ring of Trp435 fits into the same niche despite its considerably bulkier size. Additionally, the side chain forms an H-bond with the backbone carbonyl of Leu696 in an α helix (res. Asp684-Gln702). Although no apparent negative changes are observed during the variant simulation, the size difference between the swapped residues could affect the protein folding process.
c.1306G>AE436K
(3D Viewer)
Likely PathogenicGAPUncertain 1-13.869Likely Pathogenic0.997Likely PathogenicLikely Pathogenic0.829Likely Pathogenic0.56Ambiguous0.12.86Destabilizing1.71Ambiguous0.82Ambiguous-3.77Deleterious0.994Probably Damaging0.951Probably Damaging4.71Benign0.02Affected3.372901-0.4-0.94186.839.80.00.0-0.20.0XXXPotentially PathogenicThe carboxylate group of Glu436, located on the α helix (res. Met414-Glu436), forms a salt bridge with the amino group of the Lys444 side chain on an opposing α helix (res. Val441-Ser457). The backbone carbonyl of Glu436 also H-bonds with the Lys444 side chain, which helps keep the ends of the two α helices tightly connected. In contrast, in the variant simulations, the salt bridge formation with Lys444 is not possible. Instead, the repelled Lys436 side chain rotates outward, causing a change in the α helix backbone H-bonding: the amide group of Lys444 H-bonds with the carbonyl of Ala433 instead of the carbonyl of Cys432.
c.1631G>AR544Q
(3D Viewer)
Likely PathogenicGAPUncertain 16-33438874-G-A16.20e-7-10.281Likely Pathogenic0.596Likely PathogenicLikely Benign0.542Likely Pathogenic0.19Likely Benign0.20.87Ambiguous0.53Ambiguous1.40Destabilizing-2.41Neutral1.000Probably Damaging0.997Probably Damaging-1.40Pathogenic0.09Tolerated3.3735111.0-28.06
c.1635G>AM545I
(3D Viewer)
Likely PathogenicGAPUncertain 1-8.348Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.592Likely Pathogenic0.47Likely Benign0.10.14Likely Benign0.31Likely Benign0.63Ambiguous-3.61Deleterious0.935Possibly Damaging0.941Probably Damaging-1.27Pathogenic0.28Tolerated3.3735122.6-18.03
c.1349C>AA450E
(3D Viewer)
Likely PathogenicGAPUncertain 1-16.578Likely Pathogenic0.989Likely PathogenicLikely Pathogenic0.653Likely Pathogenic3.86Destabilizing0.25.23Destabilizing4.55Destabilizing1.59Destabilizing-4.67Deleterious0.999Probably Damaging0.992Probably Damaging3.38Benign0.07Tolerated3.37320-1-5.358.04240.1-82.60.00.00.70.0XXPotentially PathogenicThe methyl group of Ala450, located in an α helix (res. Asn440-Thr458), packs against hydrophobic residues in the inter-helix space (e.g., Leu692). In the variant simulations, the carboxylate group of the Glu450 side chain rotates outward, away from the hydrophobic niche, where it does not form any lasting salt bridges or H-bonds. Although the residue swap does not negatively affect the protein structure based on the simulations, it is possible that the introduction of the negatively charged residue adversely affects the folding process or tertiary assembly.
c.1354G>TV452F
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.769Likely Pathogenic0.975Likely PathogenicLikely Pathogenic0.511Likely Pathogenic9.21Destabilizing0.10.37Likely Benign4.79Destabilizing0.61Ambiguous-4.94Deleterious0.999Probably Damaging0.993Probably Damaging3.29Benign0.00Affected3.3734-1-1-1.448.04249.4-35.70.00.00.40.1XPotentially PathogenicThe iso-propyl side chain of Val452, located in the middle of an α helix (res. Val441-Ser457), packs against hydrophobic residues in the inter-helix space at the intersection of three α helices (e.g., Leu500, His453, Leu465). In the variant simulations, the larger side chain of Phe452 cannot pack against the opposing α helix (res. Leu489-Glu519) as efficiently as valine. Due to space restrictions, the phenol ring adjusts to make room by rotating slightly sideways in the inter-helix space. Besides this small and local shift, no large-scale effects on the protein structure are seen based on the simulations. However, the size difference between the swapped residues could affect the protein folding process.
c.1390T>GF464V
(3D Viewer)
Likely PathogenicGAPUncertain 1-12.254Likely Pathogenic0.994Likely PathogenicLikely Pathogenic0.592Likely Pathogenic3.61Destabilizing0.12.89Destabilizing3.25Destabilizing1.40Destabilizing-6.96Deleterious0.998Probably Damaging0.996Probably Damaging3.36Benign0.04Affected3.3734-1-11.4-48.04210.140.5-0.10.0-0.90.3XPotentially PathogenicThe phenyl ring of Phe464, located in the middle of an α helix (res. Ala461–Phe476), packs against hydrophobic residues (e.g., Met468, Leu451, Leu455, and Tyr428) in the inter-helix space formed with two other α helices (res. Asn440-Lys460 and res. Pro413-Glu436). The iso-propyl side chain of Val464 is similarly hydrophobic but considerably smaller than the original phenyl ring of Phe464. To compensate for the size difference, neighboring residues need to fill in the gap in the variant simulations.The phenolic side chain of Tyr428, located at the middle bend of an α helix (res. Glu436-Pro413), assumes a new position in the inter-helix space or rotates inward next to the third α helix (res. Asn440-Lys460) when the stable H-bond between Tyr428 and Asp467 seen in the WT simulations breaks. The residue swap also leads to the loss of the methionine-aromatic interaction between the Met468 and Phe464 side chains, which could weaken the integrity of the parent α helix (res. Ala461-Phe476). Although the simulations likely underestimate the full adverse effect of the introduced mutation during folding, the two opposing α helices (res. Ala461–Phe476 and res. Glu436-Pro413) move substantially closer to each other in the variant simulations.
c.1393C>GL465V
(3D Viewer)
Likely PathogenicGAPUncertain 1-9.893Likely Pathogenic0.838Likely PathogenicAmbiguous0.276Likely Benign2.46Destabilizing0.12.66Destabilizing2.56Destabilizing1.21Destabilizing-2.98Deleterious0.996Probably Damaging0.992Probably Damaging2.44Pathogenic0.10Tolerated3.3734210.4-14.03204.330.90.00.0-0.40.6XPotentially BenignThe iso-butyl side chain of Leu465, located in the middle of an α helix (res. Ala461–Phe476), packs with hydrophobic residues (e.g., Phe464, Met468, Tyr497, Ile494) in an inter-helix space formed with two other α helices (res. Ala461–Phe476 and res. Thr488-Gly502). In the variant simulations, the iso-propyl side chain of Val465 is equally sized and similarly hydrophobic as the original side chain of Leu465. Hence, the mutation does not exert any negative effects on the protein structure based on the variant simulations.
c.1667A>TN556I
(3D Viewer)
Likely PathogenicGAPLikely Benign 16-33438910-A-T-13.391Likely Pathogenic0.929Likely PathogenicAmbiguous0.761Likely Pathogenic0.64Ambiguous0.00.17Likely Benign0.41Likely Benign0.26Likely Benign-7.52Deleterious1.000Probably Damaging0.999Probably Damaging-1.35Pathogenic0.02Affected3.3735-3-28.0-0.94
c.1673A>GH558R
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.445Likely Pathogenic0.554AmbiguousLikely Benign0.587Likely Pathogenic-1.14Ambiguous0.1-0.23Likely Benign-0.69Ambiguous1.03Destabilizing-4.94Deleterious0.677Possibly Damaging0.239Benign-1.24Pathogenic0.14Tolerated3.373502-1.319.05
c.1394T>CL465P
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-14.824Likely Pathogenic1.000Likely PathogenicLikely Pathogenic0.778Likely Pathogenic7.18Destabilizing0.310.85Destabilizing9.02Destabilizing2.73Destabilizing-6.96Deleterious1.000Probably Damaging1.000Probably Damaging2.29Pathogenic0.00Affected3.3734-3-3-5.4-16.04211.165.90.10.0-0.20.0XPotentially PathogenicThe iso-butyl side chain of Leu465, located in the middle of an α helix (res. Ala461–Phe476), packs with hydrophobic residues (e.g., Phe464, Met468, Tyr497, Ile494) in an inter-helix space formed with two other α helices (res. Ala461–Phe476 and res. Thr488-Gly502). In the variant simulations, the cyclic five-membered pyrrolidine ring of Pro465 is not as optimal as the side chain of Leu465 for filling the three α helix hydrophobic niche. Although the residue swap does not cause a large-scale conformational shift during the simulations, the H-bond between the backbone amide group of Leu465 and the backbone carbonyl group of Ala461 is lost. This, in turn, breaks the continuity of the α helix secondary structure element.
c.1403T>AM468K
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-16.982Likely Pathogenic0.978Likely PathogenicLikely Pathogenic0.828Likely Pathogenic3.21Destabilizing0.13.30Destabilizing3.26Destabilizing2.57Destabilizing-4.61Deleterious0.878Possibly Damaging0.922Probably Damaging-1.34Pathogenic0.04Affected3.37310-1-5.8-3.02188.769.30.00.0-0.10.2XXPotentially PathogenicThe thioether group of Met468, located in the middle of an α helix (res. Ala461–Phe476), interacts with hydrophobic residues (e.g., Phe464, Leu465, Leu489) in an inter-helix space formed by two other α helices (res. Ala461–Phe476, res. Thr488–Gly502). In the variant simulations, the positively charged side chain of Lys468 rotates outward to escape the hydrophobic niche, forming an H-bond with the hydroxyl group of the Ser471 side chain and a salt bridge with the carboxylate group of the Glu472 side chain. This residue swap also disrupts the methionine-aromatic stacking with the phenyl ring of the Phe464 side chain. Although no large-scale structural changes are observed during the variant simulations, the importance of hydrophobic packing suggests that the effects could be more pronounced during protein folding.
c.1403T>CM468T
(3D Viewer)
Likely PathogenicGAPUncertain 26-33438435-T-C16.20e-7-12.399Likely Pathogenic0.862Likely PathogenicAmbiguous0.801Likely Pathogenic3.47Destabilizing0.13.10Destabilizing3.29Destabilizing1.84Destabilizing-3.85Deleterious0.994Probably Damaging0.985Probably Damaging-1.31Pathogenic0.01Affected3.3731-1-1-2.6-30.09214.647.10.00.00.10.0XPotentially PathogenicThe thioether group of Met468, located in the middle of an α helix (res. Ala461–Phe476), interacts with hydrophobic residues (e.g., Phe464, Leu465, Leu489) in an inter-helix space formed by two other α helices (res. Ala461–Phe476, res. Thr488–Gly502). In the variant simulations, the hydrophilic side chain of Thr468 does not pack favorably in the hydrophobic niche, and the methionine-aromatic stacking is lost. Although the hydroxyl group of Thr468 forms an H-bond with the backbone carbonyl group of Phe464, the integrity of the α helix is not affected in the simulations. No large-scale structural changes are observed during the variant simulations; however, due to the importance of hydrophobic packing, the effects could be more pronounced during protein folding.
c.1406C>AA469D
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.643Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.738Likely Pathogenic5.09Destabilizing0.24.16Destabilizing4.63Destabilizing1.68Destabilizing-3.48Deleterious0.999Probably Damaging0.996Probably Damaging-1.34Pathogenic0.21Tolerated3.37340-2-5.344.01237.0-58.2-0.20.10.80.1XXPotentially PathogenicThe methyl group of Ala469, located in an α helix (res. Ala461–Phe476), interacts with hydrophobic residues (e.g., Trp572, Leu588, Met470) in an inter-helix space formed by two other α helices (res. Glu582–Ser604, res. Arg563–Gly580). In the variant simulations, Asp469 introduces a negatively charged and bulky side chain into the hydrophobic niche. Consequently, the side chain of Asp469 rotates outward, allowing the carboxylate group to form a salt bridge with the guanidinium group of Arg575 on the protein surface. This interaction affects the continuity of the parent α helix (Ala461–Phe476). Due to the importance of hydrophobic packing, the structural effects could be more pronounced during actual protein folding.
c.1408A>CM470L
(3D Viewer)
Likely PathogenicGAPLikely Benign 16-33438440-A-C16.20e-7-8.993Likely Pathogenic0.406AmbiguousLikely Benign0.678Likely Pathogenic0.73Ambiguous0.10.84Ambiguous0.79Ambiguous1.04Destabilizing-2.72Deleterious0.484Possibly Damaging0.654Possibly Damaging-1.22Pathogenic0.16Tolerated3.3734421.9-18.03225.317.90.00.0-0.80.5XPotentially BenignThe thioether group of Met470, located in the middle of an α helix (res. Ala461–Phe476), interacts with hydrophobic residues in the inter-helix space (e.g., Val473, Leu558) formed by two other α helices (res. Ser604–Arg581, res. Pro562–Arg579). In the WT simulations, Met470 also packs against the positively charged guanidinium groups of Arg575, Arg429, and Arg579, which form salt bridges with the negatively charged carboxylate groups of the Asp474 and Asp467 side chains at the protein surface. In the variant simulations, the iso-butyl side chain of Leu470 packs similarly with the hydrophobic residues as methionine, resulting in no negative effects on the protein structure during the simulation.
c.1702G>TV568L
(3D Viewer)
Likely PathogenicGAPUncertain 1-9.503Likely Pathogenic0.921Likely PathogenicAmbiguous0.651Likely Pathogenic-0.30Likely Benign0.30.57Ambiguous0.14Likely Benign0.56Ambiguous-2.69Deleterious0.511Possibly Damaging0.147Benign-1.23Pathogenic0.04Affected3.373512-0.414.03
c.1726T>CC576R
(3D Viewer)
Likely PathogenicGAPConflicting 2-14.886Likely Pathogenic1.000Likely PathogenicLikely Pathogenic0.579Likely Pathogenic7.20Destabilizing1.04.09Destabilizing5.65Destabilizing1.64Destabilizing-10.88Deleterious0.999Probably Damaging0.996Probably Damaging3.38Benign0.00Affected3.3735-3-4-7.053.05
c.1738G>AG580S
(3D Viewer)
Likely PathogenicGAPUncertain 16-33440790-G-A16.20e-7-10.788Likely Pathogenic0.861Likely PathogenicAmbiguous0.644Likely Pathogenic2.84Destabilizing0.20.59Ambiguous1.72Ambiguous0.87Ambiguous-5.73Deleterious1.000Probably Damaging0.999Probably Damaging-1.23Pathogenic0.07Tolerated3.373410-0.430.03233.9-49.30.80.00.60.1XPotentially BenignGly580 is located on the outer surface in a short α-α loop turn connecting two α-helices (res. Arg563-Glu578, res. Glu582-Phe608) in the WT simulations. In the variant simulations, the side chain of Ser580 faces outward, and its hydroxyl group does not make any new or additional interactions compared to Gly580 in the WT simulations that could affect the protein structure.
c.1763T>CL588P
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.771Likely Pathogenic1.000Likely PathogenicLikely Pathogenic0.932Likely Pathogenic5.61Destabilizing0.512.91Destabilizing9.26Destabilizing2.33Destabilizing-6.97Deleterious1.000Probably Damaging1.000Probably Damaging-1.42Pathogenic0.00Affected3.3834-3-3-5.4-16.04
c.1409T>CM470T
(3D Viewer)
Likely PathogenicGAPUncertain 1-8.104Likely Pathogenic0.976Likely PathogenicLikely Pathogenic0.763Likely Pathogenic3.19Destabilizing0.12.68Destabilizing2.94Destabilizing1.49Destabilizing-5.30Deleterious0.996Probably Damaging0.985Probably Damaging-1.08Pathogenic0.24Tolerated3.3734-1-1-2.6-30.09213.846.50.00.0-0.20.2XXPotentially PathogenicThe thioether group of Met470, located in the middle of an α helix (res. Ala461–Phe476), interacts with hydrophobic residues in the inter-helix space (e.g., Val473, Leu558, Cys576, Trp572) formed by two other α helices (res. Ser604–Arg581, res. Pro562–Arg579). In the WT simulations, the Met470 side chain also packs against the positively charged guanidinium groups of Arg575, Arg429, and Arg579, which form salt bridges with the negatively charged carboxylate groups of the Asp474 and Asp467 side chains at the protein surface. In the variant simulations, the hydroxyl group of the Thr470 side chain forms an H-bond with the backbone carbonyl group of Ser466 in the α helix, potentially lowering its structural integrity. Importantly, the hydroxyl group of Thr470 also forms an H-bond with the guanidinium group of Arg575, which helps it form a more permanent salt bridge with Asp467.
c.1423C>TR475W
(3D Viewer)
Likely PathogenicGAPUncertain 16-33438455-C-T16.20e-7-13.235Likely Pathogenic0.962Likely PathogenicLikely Pathogenic0.725Likely Pathogenic1.44Ambiguous0.4-0.92Ambiguous0.26Likely Benign0.56Ambiguous-7.56Deleterious1.000Probably Damaging0.995Probably Damaging-1.45Pathogenic0.00Affected3.39282-33.630.03266.939.60.00.00.00.1XXXPotentially PathogenicIn the WT simulations, the guanidinium group of Arg475, located near the end of an α-helix (res. Ala461-Phe476), stacks with the phenyl ring of Phe476 and forms a salt bridge with Glu472. Additionally, Arg475 occasionally forms another salt bridge with the carboxylate group of Glu486 on the α-α loop connecting the two α-helices (res. Ala461-Phe476 and Leu489-Glu519) at the GAP-Ras interface. Therefore, Arg475 potentially plays a key role in positioning the loop by interacting with Glu486, which is necessary for the positioning of the “arginine finger” (Arg485) and, ultimately, for RasGTPase activation.In the variant simulations, Trp475 moves and stacks with Arg479 on the proceeding α-α loop, disrupting the terminal end of the α-helix. Lastly, the potential effect of the residue swap on the SynGAP-Ras complex formation or GTPase activation cannot be fully addressed using the SynGAP solvent-only simulations.
c.1424G>AR475Q
(3D Viewer)
Likely PathogenicGAPUncertain 26-33438456-G-A53.10e-6-12.087Likely Pathogenic0.721Likely PathogenicLikely Benign0.632Likely Pathogenic0.71Ambiguous0.10.12Likely Benign0.42Likely Benign0.82Ambiguous-3.65Deleterious1.000Probably Damaging0.991Probably Damaging-1.32Pathogenic0.01Affected3.3928111.0-28.06253.652.70.00.0-0.80.0XXXPotentially PathogenicIn the WT simulations, the guanidinium group of Arg475, located near the end of an α-helix (res. Ala461-Phe476), stacks with the phenyl ring of Phe476 and forms a salt bridge with Glu472. Additionally, Arg475 occasionally forms another salt bridge with the carboxylate group of Glu486 on the α-α loop connecting the two α-helices (res. Ala461-Phe476 and Leu489-Glu519) at the GAP-Ras interface. Therefore, Arg475 potentially plays a key role in positioning the loop by interacting with Glu486, which is necessary for the positioning of the “arginine finger” (Arg485) and, ultimately, for RasGTPase activation. In the variant simulations, Asn475 forms a hydrogen bond with Arg479 on the proceeding α-α loop. The absence of Phe476/Arg475 stacking and the Arg475-Glu472 salt bridge weakens the integrity of the terminal end of the α-helix during the variant simulations. Lastly, the potential effect of the residue swap on the SynGAP-Ras complex formation or GTPase activation cannot be fully addressed using the SynGAP solvent-only simulations.
c.1778T>CL593P
(3D Viewer)
Likely PathogenicGAPUncertain 1-13.961Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.777Likely Pathogenic5.75Destabilizing0.910.77Destabilizing8.26Destabilizing2.43Destabilizing-6.77Deleterious1.000Probably Damaging1.000Probably Damaging2.77Benign0.00Affected-3-3-5.4-16.04
c.1784T>AL595Q
(3D Viewer)
Likely PathogenicGAPUncertain 1-15.101Likely Pathogenic0.984Likely PathogenicLikely Pathogenic0.733Likely Pathogenic0.79Ambiguous0.11.40Ambiguous1.10Ambiguous1.99Destabilizing-5.97Deleterious1.000Probably Damaging1.000Probably Damaging2.75Benign0.00Affected3.3735-2-2-7.314.97
c.1784T>CL595P
(3D Viewer)
Likely PathogenicGAPUncertain 1-11.856Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.747Likely Pathogenic2.09Destabilizing0.85.88Destabilizing3.99Destabilizing1.78Destabilizing-6.97Deleterious1.000Probably Damaging1.000Probably Damaging2.72Benign0.00Affected3.3735-3-3-5.4-16.04
c.1789T>CF597L
(3D Viewer)
Likely PathogenicGAPUncertain 1-10.173Likely Pathogenic0.998Likely PathogenicLikely Pathogenic0.929Likely Pathogenic0.74Ambiguous0.12.12Destabilizing1.43Ambiguous1.20Destabilizing-5.97Deleterious0.999Probably Damaging0.994Probably Damaging-2.06Pathogenic0.13Tolerated201.0-34.02
c.1792C>GL598V
(3D Viewer)
Likely PathogenicGAPUncertain 1-10.002Likely Pathogenic0.578Likely PathogenicLikely Benign0.221Likely Benign1.89Ambiguous0.11.58Ambiguous1.74Ambiguous1.01Destabilizing-2.92Deleterious0.944Possibly Damaging0.786Possibly Damaging3.21Benign0.02Affected3.3735210.4-14.03218.429.60.00.00.80.0XPotentially BenignThe iso-butyl side chain of Leu598, located on an α helix (res. Glu582-Met603), packs hydrophobically with other hydrophobic residues in the inter-helix space (e.g., Ile602, Phe594, Ile510).In the variant simulations, Val598, which has similar size and physicochemical properties to leucine, resides in the inter-helix hydrophobic space in a similar manner to Leu598 in the WT. This causes no negative effects on the protein structure.
c.1441C>TH481Y
(3D Viewer)
Likely PathogenicGAPLikely Benign 16-33438473-C-T169.91e-6-10.910Likely Pathogenic0.565Likely PathogenicLikely Benign0.256Likely Benign-0.53Ambiguous0.1-0.46Likely Benign-0.50Ambiguous0.20Likely Benign-3.32Deleterious0.988Probably Damaging0.979Probably Damaging3.40Benign0.59Tolerated3.3733021.926.03256.5-44.40.00.00.20.2XXUncertainThe imidazole ring of the His481 side chain is located in a short helical structure (res. Glu480-Leu482) within an α-α loop connecting the two α-helices (res. Ala461-Phe476 and Leu489-Glu519) at the GAP-Ras interface. In the WT simulations, His481 alternately stacks against Arg485, Arg587, and Glu480 without a definite role. In the variant simulations, Tyr481 also alternately stacks with nearby arginine residues, including Arg485, Arg587, and Arg479. The interaction between Tyr481 and Arg479 affects the α-α loop, causing it to fold into a distorted helical structure, an effect that might be more pronounced during protein folding. Finally, the potential effect of the residue swap on SynGAP-Ras complex formation or GTPase activation cannot be fully addressed using the SynGAP solvent-only simulations.
c.1453C>TR485C
(3D Viewer)
Likely PathogenicGAPUncertain 26-33438485-C-T95.58e-6-14.294Likely Pathogenic0.976Likely PathogenicLikely Pathogenic0.597Likely Pathogenic1.00Ambiguous0.10.26Likely Benign0.63Ambiguous0.44Likely Benign-7.96Deleterious1.000Probably Damaging1.000Probably Damaging1.90Pathogenic0.00Affected3.3735-4-37.0-53.05225.599.6-0.10.0-0.30.2XUncertainThe guanidinium group of Arg485 is located in a short helical structure (res. Glu480-Leu482) within an α-α loop connecting the two α-helices (res. Ala461-Phe476 and Leu489-Glu519) at the GAP-Ras interface. The side chain of Arg485 acts as the “arginine finger” of SynGAP, playing a crucial role in Ras-GTPase activation. Consequently, the residue swap inhibits the conversion of GTP to GDP at the enzyme’s active site. Although no negative effects on the protein structure are observed during the simulations, no definite conclusions can be drawn due to the critical role of Arg485 in GTPase activation.
c.1456G>AE486K
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.545Likely Pathogenic0.988Likely PathogenicLikely Pathogenic0.435Likely Benign0.06Likely Benign0.10.37Likely Benign0.22Likely Benign0.41Likely Benign-3.58Deleterious1.000Probably Damaging0.988Probably Damaging3.40Benign0.12Tolerated3.373501-0.4-0.94206.852.1-0.30.10.20.0XXUncertainGlu486 is located in an α-α loop connecting the two α-helices (res. Ala461-Phe476 and Leu489-Glu519) at the GAP-Ras interface. It is adjacent to the arginine finger (Arg485) and is expected to closely interact with Ras. The residue swap could affect complex formation with the GTPase and its activation. In the WT simulations, the carboxylate group of Glu486 forms salt bridges with Arg485 and Arg475 on the preceding α-helix (res. Ala461-Phe476). In the variant simulations, Lys486 does not form any specific interactions. Although the amino group of the Lys486 side chain cannot form these salt bridges, no negative effects on the protein structure are observed. Nevertheless, the potential role of Glu486 in SynGAP-Ras complex formation or GTPase activation cannot be fully addressed using the SynGAP solvent-only simulations, and no definite conclusions can be drawn.
c.1465C>TL489F
(3D Viewer)
Likely PathogenicGAPUncertain 26-33438497-C-T16.20e-7-12.066Likely Pathogenic0.965Likely PathogenicLikely Pathogenic0.724Likely Pathogenic1.72Ambiguous0.51.14Ambiguous1.43Ambiguous0.56Ambiguous-3.76Deleterious1.000Probably Damaging0.997Probably Damaging-1.51Pathogenic0.01Affected3.373520-1.034.02246.4-17.80.00.00.60.1XPotentially BenignThe iso-butyl side chain of Leu489, located in the α-helix (res. Leu489-Glu519) within an inter-helix space of four helices (res. Ala461-Phe476, res. Val441-Ser457, and res. Met414-Glu436), packs with hydrophobic residues (e.g., Cys432, Ala448, Lys444, Ala493, Val447, Met468) in the inter-helix space. In the variant simulations, the phenyl ring of the Phe489 side chain can also pack favorably in the hydrophobic region. However, due to the size difference, the aromatic side chain of Phe489 tends to reposition to escape the tight region to accommodate the larger side chain, stacking with Lys444. Although no apparent negative changes are observed during the variant simulation, the size difference between the swapped residues could affect the protein folding process.
c.1466T>CL489P
(3D Viewer)
Likely PathogenicGAPConflicting 2-13.520Likely Pathogenic0.997Likely PathogenicLikely Pathogenic0.939Likely Pathogenic2.50Destabilizing0.14.69Destabilizing3.60Destabilizing1.73Destabilizing-6.74Deleterious1.000Probably Damaging1.000Probably Damaging-1.56Pathogenic0.00Affected3.3735-3-3-5.4-16.04209.961.90.10.00.60.1XPotentially PathogenicThe iso-butyl side chain of Leu489, located in the α-helix (res. Leu489-Glu519) within an inter-helix space of four helices (res. Ala461-Phe476, res. Val441-Ser457, and res. Met414-Glu436), packs with hydrophobic residues (e.g., Cys432, Ala448, Lys444, Ala493, Val447, Met468). In the variant simulations, Pro489 is located near the beginning of the α-helix, so the residue swap with Leu489 does not affect the continuity of the secondary structure element. However, the side chain of proline is not as optimal as that of leucine for maintaining hydrophobic packing with nearby residues (e.g., Ala448, Lys444). Additionally, the consistently maintained hydrogen bond interaction between the backbone amide group of Leu489 and the carbonyl of Glu436 is lost due to the residue swap, potentially affecting the tertiary structure integrity.
c.1835A>CQ612P
(3D Viewer)
Likely PathogenicGAPUncertain 1-9.684Likely Pathogenic0.673Likely PathogenicLikely Benign0.671Likely Pathogenic-0.19Likely Benign0.33.06Destabilizing1.44Ambiguous0.56Ambiguous-5.84Deleterious1.000Probably Damaging1.000Probably Damaging-1.31Pathogenic0.19Tolerated0-11.9-31.01
c.1855A>TT619S
(3D Viewer)
Likely PathogenicGAPUncertain 1-8.608Likely Pathogenic0.677Likely PathogenicLikely Benign0.602Likely Pathogenic1.09Ambiguous0.21.35Ambiguous1.22Ambiguous0.85Ambiguous-3.42Deleterious0.999Probably Damaging0.998Probably Damaging-1.30Pathogenic0.05Affected3.373511-0.1-14.03
c.1873C>GL625VLikely PathogenicGAPUncertain 1-11.319Likely Pathogenic0.833Likely PathogenicAmbiguous0.480Likely Benign1.80Ambiguous0.71.69Ambiguous1.75Ambiguous1.42Destabilizing-2.96Deleterious0.998Probably Damaging0.992Probably Damaging3.07Benign0.01Affected210.4-14.03
c.1877T>CI626TLikely PathogenicGAPUncertain 1-10.420Likely Pathogenic0.946Likely PathogenicAmbiguous0.640Likely Pathogenic2.94Destabilizing0.12.70Destabilizing2.82Destabilizing2.23Destabilizing-4.18Deleterious1.000Probably Damaging1.000Probably Damaging3.04Benign0.00Affected0-1-5.2-12.05
c.1481T>GI494R
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-15.758Likely Pathogenic0.995Likely PathogenicLikely Pathogenic0.911Likely Pathogenic6.71Destabilizing0.33.40Destabilizing5.06Destabilizing2.19Destabilizing-6.43Deleterious0.999Probably Damaging0.957Probably Damaging-1.41Pathogenic0.00Affected3.3735-2-3-9.043.03273.9-59.80.00.00.00.1XXXXPotentially PathogenicThe sec-butyl side chain of Ile494, located in an α-helix (res. Leu489-Glu519), packs against hydrophobic residues (e.g., Phe484, Leu465, Trp572, Ala493, Met468) in an inter-helix space (res. Leu489-Glu519 and res. Ala461-Phe476). In the variant simulations, the bulkier and positively charged residue, Arg494, weakens the integrity of the opposing helix. Additionally, the bulkier Arg494 stacks with Phe484, causing the α-helices to move farther apart to accommodate it. This mutation could have substantial negative effects due to the fundamental role of hydrophobic packing, which is disrupted by Arg494 during protein folding.
c.1485A>CE495D
(3D Viewer)
Likely PathogenicGAPConflicting 2-3.574Likely Benign0.958Likely PathogenicLikely Pathogenic0.566Likely Pathogenic1.39Ambiguous0.11.03Ambiguous1.21Ambiguous0.98Ambiguous-2.52Deleterious0.998Probably Damaging0.989Probably Damaging-1.41Pathogenic0.17Tolerated3.3735320.0-14.03220.638.80.00.00.10.1XXUncertainGlu495 is located in the α-helix (res. Leu489-Glu519), and its carboxylate group forms salt bridges with the neighboring Lys492 and with Arg596 on an opposing α-helix (res. Glu582-Met603) in the WT simulations. In the variant simulations, the acidic carboxylate side chain of Asp495 can also form salt bridges with both Lys492 and Arg596. However, the shorter side chain of aspartate tends to favor forming a salt bridge with the nearby Arg499 on the same α-helix instead. Asp495 might not maintain the salt bridge with Arg596 on the opposing α-helix as efficiently as Glu495 in the WT, potentially weakening the tertiary structure. Regardless, the potential negative effect is likely to be minor, with no deleterious effects observed on the protein structure during the simulations. However, due to its location at the GAP-Ras interface, the effect of the residue swap on SynGAP-Ras complex formation or GTPase activation cannot be fully addressed using the SynGAP solvent-only simulations.
c.1487A>GE496G
(3D Viewer)
Likely PathogenicGAPUncertain 1-13.529Likely Pathogenic0.850Likely PathogenicAmbiguous0.825Likely Pathogenic1.83Ambiguous0.11.76Ambiguous1.80Ambiguous0.92Ambiguous-6.16Deleterious1.000Probably Damaging0.999Probably Damaging-1.45Pathogenic0.02Affected3.37350-23.1-72.06173.9103.10.00.0-0.70.0XXPotentially PathogenicGlu496 is located in the α-helix (res. Leu489-Glu519), and its carboxylate group forms salt bridges with the neighbouring residues Lys492 and Arg499 in the WT simulations. Glu496 also forms a hydrogen bond with Ser449 on an opposing helix (res. Val441-Ser457). In the variant simulations, Gly496 cannot form these salt bridges, which could weaken the secondary structure. Additionally, the loss of the hydrogen bond with Ser449 on the opposite helix can weaken the tertiary structure assembly. Moreover, glycine is an α-helix breaker, and it is seen to weaken the integrity of the helix as the hydrogen bonding between the backbone atoms of Gly496 and Ala493 breaks down. Also, due to its location at the GAP-Ras interface, the interaction of Glu496 with Arg499 and Lys492 might play a role in complex association and stability, which cannot be fully addressed using the SynGAP solvent-only simulations.
c.1490A>GY497C
(3D Viewer)
Likely PathogenicGAPUncertain 1-11.872Likely Pathogenic0.948Likely PathogenicAmbiguous0.806Likely Pathogenic3.88Destabilizing0.14.76Destabilizing4.32Destabilizing1.40Destabilizing-8.82Deleterious1.000Probably Damaging0.995Probably Damaging-1.65Pathogenic0.03Affected3.37350-23.8-60.04209.959.1-0.10.0-0.30.1XXPotentially PathogenicTyr497 is located in the α-helix (res. Leu489-Glu519) within the inter-helix space of four α-helices (res. Leu489-Ile501, res. Val441-Ser457, res. Arg563-Glu578, res. Ala461-Val473). In the WT simulations, the phenol ring of Tyr497 hydrophobically packs with other residues in the inter-helix space (e.g., Leu465, Leu565, Val568). The hydroxyl group of Tyr497 also alternately forms hydrogen bonds with the carboxylate side chain of Gln456 and the backbone carbonyl of Glu564. Thus, Tyr497 plays a role in the folding and maintenance of the tertiary structure assembly between these four helices.In the variant simulations, the comparatively smaller residue, Cys497, cannot maintain any of the interactions seen with Tyr497 in the WT. Although no severe deleterious consequences are observed in the simulations, the structural effects could be more pronounced during actual protein folding. Indeed, the tertiary structure is seen to slightly break apart in the variant simulations.
c.1942T>CF648LLikely PathogenicGAPUncertain 1-9.296Likely Pathogenic0.999Likely PathogenicLikely Pathogenic0.468Likely Benign2.71Destabilizing0.82.08Destabilizing2.40Destabilizing1.04Destabilizing-5.98Deleterious0.999Probably Damaging0.976Probably Damaging3.45Benign0.08Tolerated201.0-34.02
c.1505G>AG502D
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.796Likely Pathogenic0.994Likely PathogenicLikely Pathogenic0.915Likely Pathogenic3.79Destabilizing0.95.69Destabilizing4.74Destabilizing1.38Destabilizing-6.80Deleterious0.999Probably Damaging0.977Probably Damaging-1.66Pathogenic0.00Affected3.37351-1-3.158.04224.2-80.0-0.80.70.60.3XXXPotentially PathogenicGly502 is located in a hinge in the middle of an α-helix (res. Leu489-Glu519). In the WT, Gly502 acts as an α-helix breaker due to its lack of a side chain, facilitating a bend in the middle of the α-helix. In the variant simulations, the carboxylate group of Asp502 forms hydrogen bonds with neighboring residues (e.g., Ser677, Lys504), disrupting the hinge. Additionally, Asp502 struggles to fit into the α-helix hinge and cannot generate a similar bend as Gly502, which would drastically affect the secondary structure during folding. Thus, the deleterious effect seen in the simulations is likely an underestimate of the impact of the residue swap on the protein structure during protein folding.
c.1517T>CL506P
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic1-12.088Likely Pathogenic0.998Likely PathogenicLikely Pathogenic0.737Likely Pathogenic5.48Destabilizing0.710.19Destabilizing7.84Destabilizing2.50Destabilizing-6.96Deleterious1.000Probably Damaging1.000Probably Damaging1.55Pathogenic0.00Affected3.3735-3-3-5.4-16.04182.664.90.10.00.20.1XPotentially PathogenicLeu506 is located in the middle of an α-helix (res. Gly502-Tyr518) within the inter-helix space of two helices (res. Gly502-Tyr518 and res. Glu582-Met603). In the WT simulations, the iso-butyl side chain of Leu506 hydrophobically packs with residues in the inter-helix space (e.g., Ile510, Phe597, Leu598, Ala601). In the variant simulations, the cyclic five-membered pyrrolidine ring of Pro506 is not as optimal as Leu506 for hydrophobic packing with nearby residues. Additionally, Pro506 cannot maintain the hydrogen bond with the backbone oxygen of Gly502 as Leu506 does in the WT, which disrupts the secondary structure element.
c.1529T>GI510S
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-11.661Likely Pathogenic0.955Likely PathogenicAmbiguous0.926Likely Pathogenic4.00Destabilizing0.13.78Destabilizing3.89Destabilizing2.34Destabilizing-4.63Deleterious1.000Probably Damaging0.999Probably Damaging-1.44Pathogenic0.00Affected3.3735-1-2-5.3-26.08201.445.9-0.40.20.00.3XPotentially PathogenicIle510 is located in the middle of an α-helix (res. Gly502-Tyr518) within the inter-helix space of three helices (res. Gly502-Tyr518, Ala533-Val560, and res. Glu582-Met603). In the WT simulations, the sec-butyl side chain of Ile510 hydrophobically packs with other residues in the inter-helix space (e.g., Leu506, Leu610, Ile514, Ile602, Leu598). In the variant simulations, the hydroxyl group of Ser510 forms a hydrogen bond with the backbone atoms of Leu506 and Gly511 in the same α-helix, which could further weaken the α-helix integrity. This α-helix already shows weakness in the WT simulations due to Gly511. Although the simulations do not show large-scale effects, the residue swap could have a substantial impact due to the fundamental role of hydrophobic packing during protein folding.
c.1531G>AG511R
(3D Viewer)
Likely PathogenicGAPLikely Pathogenic 1-11.327Likely Pathogenic0.991Likely PathogenicLikely Pathogenic0.416Likely Benign1.94Ambiguous0.31.32Ambiguous1.63Ambiguous0.94Ambiguous-7.72Deleterious1.000Probably Damaging1.000Probably Damaging3.26Benign0.06Tolerated3.3735-3-2-4.199.14279.4-159.90.00.00.70.1XXPotentially PathogenicGly511 is located in an α-helix (res. Gly502-Tyr518), facing hydrophobic residues in an inter-helix space (e.g., Leu610, Ile514) in the WT simulations. In contrast, in the variant simulations, the bulkier and positively charged guanidinium side chain of Arg511 forms a salt bridge with the carboxylate group of Glu217 or hydrogen bonds with the backbone carbonyl group of Leu610. Although the residue swap introduces a third positively charged residue in close vicinity (Arg511, Lys507, Arg515), the protein structure seems to remain stable in the variant simulations. Importantly, according to ClinVar, the residue swap alters the last nucleotide of an exon and is predicted to destroy the splice donor site, resulting in aberrant splicing and pathogenic status.10.1016/j.ajhg.2020.11.011
c.1970G>TW657L
(3D Viewer)
Likely PathogenicGAPUncertain 1-14.411Likely Pathogenic0.960Likely PathogenicLikely Pathogenic0.213Likely Benign0.14Likely Benign0.10.73Ambiguous0.44Likely Benign0.87Ambiguous-10.86Deleterious0.277Benign0.078Benign3.52Benign0.14Tolerated3.3924-2-24.7-73.05
c.1971G>CW657CLikely PathogenicGAPUncertain 1-12.035Likely Pathogenic0.997Likely PathogenicLikely Pathogenic0.463Likely Benign2.74Destabilizing0.31.69Ambiguous2.22Destabilizing1.30Destabilizing-11.06Deleterious1.000Probably Damaging0.982Probably Damaging3.43Benign0.03Affected-8-23.4-83.07
c.1531G>CG511R
(3D Viewer)
Likely PathogenicGAPPathogenic 1-11.327Likely Pathogenic0.991Likely PathogenicLikely Pathogenic0.415Likely Benign1.94Ambiguous0.31.32Ambiguous1.63Ambiguous0.94Ambiguous-7.72Deleterious1.000Probably Damaging1.000Probably Damaging3.26Benign0.06Tolerated3.3735-3-2-4.199.14279.4-159.90.00.00.70.1XXPotentially PathogenicGly511 is located in an α-helix (res. Gly502-Tyr518), facing hydrophobic residues in an inter-helix space (e.g., Leu610, Ile514) in the WT simulations. In contrast, in the variant simulations, the bulkier and positively charged guanidinium side chain of Arg511 forms a salt bridge with the carboxylate group of Glu217 or hydrogen bonds with the backbone carbonyl group of Leu610. Although the residue swap introduces a third positively charged residue in close vicinity (Arg511, Lys507, Arg515), the protein structure seems to remain stable in the variant simulations. Importantly, according to ClinVar, the residue swap alters the last nucleotide of an exon and is predicted to destroy the splice donor site, resulting in aberrant splicing and pathogenic status.10.1016/j.ajhg.2020.11.011
c.1544G>AR515H
(3D Viewer)
Likely PathogenicGAPUncertain 16-33438787-G-A31.86e-6-10.774Likely Pathogenic0.337Likely BenignLikely Benign0.730Likely Pathogenic1.07Ambiguous0.20.74Ambiguous0.91Ambiguous1.09Destabilizing-3.44Deleterious1.000Probably Damaging0.998Probably Damaging-1.32Pathogenic0.01Affected3.3735201.3-19.05239.277.80.00.00.40.2XPotentially BenignThe guanidinium group of Arg515, located in the middle of an α-helix at the GAP domain (res. Gly502-Tyr518), forms salt bridges with the carboxylate groups of Glu512 on the same helix and Glu217 on a loop in the PH domain. Additionally, the positively charged Arg515 side chain forms hydrogen bonds with Leu610 and Gln612 in an opposing loop (res. Gly609-Asp616). In contrast, in the variant simulations, the imidazole ring of His515 cannot form salt bridges with either of the acidic residues, and its side chain is too short to form hydrogen bonds with the loop residues. Accordingly, the residue swap could weaken the tertiary structure assembly of the protein. Due to the missing N-terminal part of the SynGAP model, the effect could be largely underestimated or missing. Notably, the doubly protonated and positively charged form of histidine was not simulated here.

Found 742 rows. Page 3/4 |